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The occurrence of Complement in human milk indicates the presence of innate 
immune components of maternal origin and their putative defensive role in the 
neonatal gut.  In order to ascertain the status of Complement in bovine milk, it was 
necessary to validate the suitability of the Complement-sensitive bacterial 
sequestration assay used to monitor human milk.  The relative bacteriostatic effects, 
expressed as a differential between the initial and final assay counts following 
inhibition of the E. coli O111 marker strain were, 6.20 and 6.06 log CFU/ml  for raw 
bovine and human milks, respectively.  Lower levels of Complement activity 
measured in pasteurised and low-fat milks were observed during the course of 
heatinactivation studies, while gravity separation of cream over a 24 h period 
confirmed a greater degree of attachment by Complement to the rising cream layer. 
The E. coli O111 sequestration assay strain had restricted growth of 7.5 and 8.2 
CFU/ml in the higher and lower gravity-separated fractions, respectively.  An animal 
health effect was observed, with Complement appearing to be more active in milk 
samples from cows with a higher somatic cell counts (SCC).  Inducing sub-clinical 
mastitis in the healthy quarter of a lactating cow confirmed that increased 
Complement activity effect was local to the affected quarter and not manifested 
systemically.                                                          
Complement activity levels varied in the milks of 7 commercially important 
prominent dairy breeds and crossbreeds surveyed.  Both the Norwegian Red and 
Kerry breed cows stood out as having higher Complement activity (6.25 and 6.92 
CFU/ml, respectively); these two breeds are known to have stronger immunity and a 
better capacity to resist mastitic infection.  
x  
  
The findings of this study have implications for both milk production and 
processing disciplines. In order to retain the antimicrobial efficacy associated with 
Complement in raw bovine milk, milder process treatments than hitherto practised in 
industry should be adopted.  
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Chapter I Literature Review  
  
  
  
  
  
  
  
  
  
1.1. Introduction  
  
Human breast milk (HBM) is the universally preferred source of nutrition for the 
neonate, as it contains the correct balance of nutrients and functional components to 
20  
        
both protect and promote early growth during the initial stages of life.  These protective 
elements of HBM support the new-born in these critical stages pending the 
development of its own immune system.  In the event that HBM is replaced with 
regular first age infant formulae, it is essential that it meets the compositional and 
nutritional requirements as set out by Codex Alimentarius for infants during the first 
months of life (Codex Standard for Infant formula, 1981).  Over the years, considerable 
strides have been made to ‘humanise’, i.e., align the composition of bovine milk to 
resemble more closely that of HBM.  However as of yet, there is no requirement which 
sets out the levels of protection in the form of defensive components which should be 
incorporated in infant milk formula.  Consequently, formula fed infants are likely to 
be at a disadvantage by not having the comprehensive physiological protection 
afforded by components of HBM.  Several studies report that the absence of 
breastfeeding may be associated with an increased incidence of infection, increased 
possibility of childhood obesity, type 1 and type 2 diabetes, and leukemia, (Lönnerdal 
et al., 1976, Kostraba et al., 1993, Horta et al., 2007).     
   
It is well known that HBM provides passive protective elements from the mother’s 
immune system such as Immunoglobulin A (IgA), Immunoglobulin G (IgG), 
Immunoglobulin M (IgM) as well as non-immune components like lactoferrin, 
lactoperoxidase and lipids.  Human milk shares many of these components with bovine 
milk (Hamosh et al., 1999).  In addition, bovine milk is reported to provide other 
biologically active compounds that can defend neonates, such as antibacterial peptides, 
antimicrobial proteins, oligosaccharides, and lipids, besides many other components 
at low concentrations.  Complement is another protective component in HBM, which 
features prominently in the innate immune response and also contributes to the adapted 
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immune system (Carroll, 2004, Ogundele, 2001).  The Complement system is 
represented by a multi-step pathway or cascade consisting of more than 30 serum 
proteins and cell surface receptors that act in a number of ways, from cell lysis to the 
promotion of specific B and T cell responses.    
  
It is postulated that the Complement components bind to the milk fat globule 
membrane (MFGM) where in the presence of bacteria, the activation of the  
Complement reaction cascade is triggered (Ogundele, 1999a).  It is thought that the  
MFGM in human milk acts as a preferred site for the initiation and activation of the 
Complement reaction cascade, localising concentration so as to apply maximal effect 
on the membrane-bound antigens.  Furthermore, this association may increase the 
sequestration by MFGM of other antigens present.  As well as direct antimicrobial 
effects, Complement can limit the development of harmful immune complexes and 
may sustain the antigens by coating with covalently attached fragments (Complement 
component C3) which inhibit the precipitation of Immunoglobulins (Igs) and promote 
uptake and removal by phagocytes (Korhonen et al., 2000).  Another constituent of 
interest, Complement component C5a, is a pro-inflammatory mediator and is described 
as one of the most biologically significant peptides (Rainard, 2003).  While C5a is 
reported to be very low in normal milk (Rainard, 1998), it is speculated that it may be 
produced by the activation of the Complement with zymosan, indicating that a C5-
convertase can be assembled in normal milk.  Further effects of the Complement 
system include the formation of a membrane-attacking complex which can be 
damaging to bacteria (Janeway Jr et al., 2001).    
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1.2. Nutritional and immune composition of human milk  
  
The neonatal period is one of the most critical and vulnerable periods in mammalian 
life.  Early post-partum milk secretions in the form of colostrum are species specific 
in terms of composition and physiological effects.  Within days, the compositions of 
both human and bovine milk adjust to the levels typically associated with their 
respective full lactations (Kulski and Hartmann, 1981).  Moreover, its composition 
varies with lactation stage and in line with the infants evolving nutritional needs (“The  
Surgeon General’s Call to Action to Support Breastfeeding”, 2011).  A comprehensive 
understanding of human milk composition provides an important guideline for the 
management of infant feeding, particularly of fragile, high-risk infants.  Such an 
understanding is also critical for the adaptation of bovine milk and the potential impact 
of processing induced effects.   
  
Considerable strides have been made to mimic HBM, e.g., reversal of the ratio of 
casein to whey proteins and realignment of fatty acids, quality and quantity of 
nonprotein nitrogen, availability of immunoglobulins as well as other immune 
components (Emmett and Rogers, 1997).  However, care is required with the addition 
of bioactive components derived from bovine milk to infant milk formula (IMF).  For 
example, in the case of osteopontin, the bovine form differs from that found HBM in 
primary structure, as well as some post-translational modifications.  Thus, it is 
advisable to carry out in vitro studies, along with animal models or clinical trials in 
order to assess the overall effect and potential benefits of including these proteins  
(Lönnerdal, 2014).    
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Human milk is the confluence of sources, i.e., component synthesis in the lactocyte, 
permeation of constituents of dietary origin, and those released from maternal stores 
(Ballard and Morrow, 2013).  Human maternal lactation is typically divided into three 
time periods: colostrum during the first 5 days post-partum; transitional milk during 
the second 5 days post-partum and mature milk thereafter.  The general composition 
of mature human milk is; 3%-5% fat, 0.8%-0.9% protein, 6.9%-7.2% carbohydrate 
and 0.2% mineral constituents (Jenness, 1979).  However, protein and fat contents vary 
in earlier stage milk forms, i.e., colostrum.  The total protein content declines from 
approx. 14-16 g/l during early lactation to 8-10 g/l at the 3-4 month stage of lactation 
and finally 7-8 g/l at 6 months and thereafter (Lönnerdal, 2003).  The major proteins 
in human milk are beta-casein, alpha-lactalbumin, lactoferrin, IgA, lysozyme, and 
serum albumin, while the essential amino acid pattern optimally matches infant 
nutrition needs.  The fat content of HBM is characterized by high contents of palmitic 
and oleic acids.  The main mineral components are Na, K, Ca, Mg, P, and Cl.  In HBM, 
like other mammalian milks, the lipid phase is dispersed as droplets which are 
surrounded by a MFGM generated by the blebbing process in the mammary gland 
cells.  MFGM is comprised mostly of phospholipids, specific proteins and as well as 
cholesterol.  In the case of HBM, the fat globules range in size from approx. 0.1μm up 
to 15μm (Gallier et al., 2015).     
  
HBM contains a number of bioactive components that are regarded as either essential 
or non-essential in terms of their effect on human health (Biesalski et al., 2009).   
Maternal milk provides passive protection to the young neonate by providing immune 
constituents and bioactive components which may act synergistically (Korhonen et al., 
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2009).  More recently, the Complement system has also been implicated in the 
provision of protection against the continual threat of foreign invaders (Ogundele, 
1999b).  A previous study suggested that the presence of Complement secretion plays 
an important role in the initiation of localised immune reactions (Cole et al., 1982).  It 
was originally believed that Complement was present in milk at such low levels that it 
was unlikely to have any biological effect (Mueller et al., 1982), however, recent 
evidence proves the opposite effect may be true (Rainard and Riollet, 2006).  As 
discussed later, the Complement system has three major pathways; classical, 
alternative and lectin.  The classical Complement pathway is activated by antibody– 
antigen complexes on the bacterial surface, whereas the alternative and 
mannosebinding lectin pathways are activated directly by bacterial cell surface 
components.  The classical pathway of the Complement system appears to be low in 
bovine milk, while, on the other hand, the identification of components C3b and C3bi, 
as well as C5-convertase, indicates that the alternative pathway is active (Yingming 
Zhao, 1997, Rainard, 2003).  This pathway is activated in plasma whilst in the fluid 
phase it is induced by a spontaneous conformational change of C3, which provokes 
formation of an enzyme complex that cleaves further molecules in the cascade and sets 
in motion an amplification reaction that activates the Complement (Zipfel and Skerka, 
2008).  The benefits of such innate immunological components in breast milk has been 
credited with improved developmental  in premature infants, and reduced incidence of 
GI infections, obesity and eczema (Von Kries et al., 1999, Howie et al.,  
1990).    
  
1.3. Milk fat globule membrane – MFGM  
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The MFGM is a biological membrane that envelopes the fat droplets dispersed in Milk.  
MFGM is understood to be a phospholipid tri-layer that carries proteins and lipids from 
the endoplasmic reticulum membrane and the mammary epithelium cells’ membrane 
(Mather and Keenan, 1975).  As well as being a membrane enveloping the milk fat 
globules in milk, these colloidal assemblies have been identified as the carriers of fat-
soluble nutrients as well as biologically active molecules, which include 
phospholipids, sphingolipids, cholesterol and other MFGM proteins (Lopez, 2011).  
Milk fat globules and their surrounding MFGM originate from the plasma membrane 
and more specifically the endoplasmic reticulum during milk secretion (Zaczek and  
Keenan, 1990).    
  
It has been found that the MFGM is comprised of a number of proteins and lipids 
which represent between 1–2% of the protein in milk (Le et al., 2013).  Although its 
composition is highly variable, it is mostly comprised of glycoproteins, phospholipids 
and sphingolipids (Table 1.1), which are of considerable interest because of their 
potential bioactivity.  The phospholipid fractions include phosphatidylethanolamine 
and phosphatidylcholine and in lesser quantities phosphatidylserine and 
phosphatidylinositol.  The sphingolipids include sphingomyelin as well as ceramides 
and gangliosides (Park, 2009).  The bioactive proteins associated with the MFGM are 
known to have anti-carcinogenic properties as well as moderating the progression of 
some age-related diseases, stress responses, apoptosis and development of  
Alzheimer’s disease (Spitsberg, 2005).  Furthermore, butyric acid and butyrate are 
capable of inhibiting development of colon and mammary tumours (Parodi, 1998).   
Mostly, MFGM protects against bacteria and viruses by binding to their outer layers.  
Mucin components associated with the MFGM (MUC-1 and MUC-15) have been  
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identified as having a protective role by inhibiting epithelial cell apoptosis.  Moreover, 
they play a significant role regulating chemokine secretion in gastrointestinal tissue 
(Chatterton et al., 2013).  CD14 is a minor constituent of MFGM that is recognised as 
an important receptor that plays a key role in the innate recognition of bacteria. This 
component is believed to trigger a potent immune response and may also have a 
significant role in education of the neonatal immune system (Bianchi et al., 2009).  
Milk also contains hormones, growth factors and cytokines that are biologically active 
at low concentrations (Friel and Qasem, 2016).    
  
Component  mg/100g fat globules  mg/100g MFGM dry matter  
Protein  1800  70  
Phospholipids  650  25  
Cerobrosides  80  3  
Cholesterol  40  2  
Carotenoids + Vit. A  0.04  0.0  
Iron (Fe)  0.3  0.0  
Copper (Cu)  0.01  0.0  
Total  >2570  100  
  
Table 1.1 Average composition of MFGM (adapted from Dewettinck et al., 2008).  
  
Human milk fat globule membrane (HMFGM) is known to prevent bacterial  
adherence that causes agglutination (Hamosh 2001).  Moreover, it is hypothesised that 
MFGM provides the major site where Complement is activated and comes into contact 
with particulate antigens (Ogundele, 1999a).    
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The clustering of milk fat globules during cream separation has been likened to the 
agglutination of bacteria or red blood cells due to the action of IgM (Walstra, 1995).  
It is hypothesised that cold agglutination involves three components; MFGs, IgM and 
the skim milk membrane (SMM).  The indigenous immunoglobulins precipitate onto 
fat globules at low temperatures, and thus, are termed cryoglobulins   These 
components interact using carbohydrate moieties and it is reported the fat globules 
cluster to a limited degree by IgM alone; however, clustering is improved in the 
presence of SMM, which may act as a cross-linking agent (Euber and Brunner, 1984).  
It is apparent that this process is accelerated by cryoglobulins, as seen from the fact 
that ovine, caprine or buffalo milk, which lack cryoglobulins, cream much more slowly 
than bovine milk (Huppertz and Kelly, 2006).  
  
1.4. Antimicrobial agents in Bovine Milk  
  
Transfer of antimicrobial components during milk secretion is a key biological 
function which provides protection to the suckling neonate.  It is reasonable to expect 
that maximum protection is transferred during the early stages of life via colostrum 
and transition to early lactation milk.  Within milk, a range of proteins, peptides, 
enzymes and complex carbohydrates are known to possess antimicrobial activities, by 
which they restrict the growth of and / or clear pathogenic bacteria, viruses and fungi.  
A brief overview of these components is now outlined.  
Immunoglobulins  
Immunoglobulins (Igs), generically referred to as antibodies, constitute 1-2% of total 
protein in normal bovine milk and are sub-divided into different classes based on their 
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structure and functions.  The major immunoglobulins identified in both human and 
bovine milk are IgA, IgG and IgM (Korhonen and Marnila, 2009).  Ig preparations 
derived from human serum, as well as bovine colostrum and serum, have proven 
effective in human clinical trials when treating a variety of enteric microbial infections 
and other conditions which cause diarrhoea (Jasion and Burnett, 2005). The heat-labile 
nature of Igs raises concerns as to the effect of processing on their biological efficacy. 
In the case of IgG, a high percentage of the bioactivity is retained following processing  
e.g. 59 – 76% after high temperature, short time (HTST) treatment (Chan et al., 1995).  
However, some caution is required at the point of digestion, as IgG binds only to 
antigens within the gastrointestinal (GI) tract if the Fab (fragment antigen-binding) 
structure is intact and not extensively denatured through exposure to acidic pH or the 
action of digestive proteolytic enzymes (Jasion and Burnett, 2005).  Immunoglobulins 
also act synergistically along with other defence factors in milk such as lactoferrin, 
and the Complement system (Ellison, 1994); in fact, possibly one of the Igs’ most 
important functions is the activation of Complement-mediated bacteriolytic reactions  
(Korhonen et al., 2000).    
  
Lactoferrin  
Lactoferrin is an iron-binding glycoprotein that is considered to be part of the innate 
immune system, but has a capacity to take part in specific immune reactions (Legrand 
et al., 2005).  While occurring at low concentration, lactoferrin levels are considerably 
higher in human compared to bovine milk. Moreover, levels are elevated (~7g/L) in 
both colostrum and first milkings (Farnaud and Evans, 2003) which emphasises its 
importance in early life nutritional and biological support.  A number of mechanisms 
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have been postulated by which lactoferrin is effective as an antimicrobial agent, e.g.(i) 
withholding iron from iron-requiring pathogens (Ellison, 1994), (ii) binding of the 
microbial membrane by interacting with lipopolysaccharide (LPS) on the surface 
(Appelmelk, et al., 1994), and (iii) prevention of microbial attachment to epithelial 
cells or enterocytes (González-Chávez et al., 2009).  The amino terminal domain of 
lactoferrin, responsible for its outer membrane effects, has been identified as the 
lactoferricin peptide, which is released on digestion by pepsin.  Lactoferricin operates 
by degrading the protein structures which are essential for bacterial attachment and 
invasion (Gifford et al., 2005). The broad bactericidal activity of lactoferricin and its 
effect on bacterial morphology are quite distinct from those of whole lactoferrin  
(Ellison, 1994).  
  
Lactoperoxidase  
The ‘Lactoperoxidase System of Raw Milk Preservation’ is currently the only 
approved method of raw milk preservation, apart from refrigeration, adopted by Codex  
Alimentarius as a guideline in 1991 (CAC GL 13/91). The Lactoperoxidase System 
(LP-system) operates by reactivation of the enzyme lactoperoxidase naturally present 
in raw milk by the addition of thiocyanate and a source of peroxide. This results in a 
blocking of bacterial metabolism thereby preventing the multiplication of bacteria 
present in the milk. The effect is classified as bacteriostatic and of limited duration due 
to its temperature dependency. Heme-containing peroxidase acts in combination with 
hydrogen peroxide to form hypothiocyanate that kills both gram-positive and gram-
negative bacteria.   The lactoperoxidase reaction with nitrite to produce nitric dioxide 
induces interactions with xanthine oxidase (XO) to regulate local inflammatory 
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responses and control infectious events (Silanikove et al., 2005).  This native 
antimicrobial LP-system present in milk is actively encouraged in developing dairy 
countries, particularly in areas where farmers experience problems with inadequate 
milk storage and transport logistics. The LP-system provides badly needed shelf-life 
of milk samples collected under tropical conditions, and supports farm sales outside of 
its immediate catchment (Asaah et al, 2007, Bennett, 2005).   
  
Lysozyme  
Lysozyme is a bacterial hydrolase that catalyses the breakdown of peptidoglycan 
polymers of the bacterial cell wall at the β1-4 bonds between N-acetylmuramic (NAM) 
acid and N-acetylglucosamine (NAG) residues, thereby lysing sensitive bacteria.  
Apart from its bacterial effects, lysozyme’s ability to inhibit viruses and eukaryotic 
microorganisms that are devoid of a typical peptidoglycan layer suggests the 
involvement of mechanisms other than hydrolytic activity, most probably an 
interaction with the lipid layer of the inner membrane.  However, microorganisms with 
a natural resistance to lysozyme are common, and many mechanisms of resistance 
have been discussed (Benkerroum, 2008). As an example of commercial application, 
egg-white sourced lysozyme is employed as an antimicrobial to lyse Clostridium 
tyrobutyricum, a spore-forming spoilage bacterium that is particularly associated with  
‘gas blowing’ in brined-cheeses such as Gouda and Grana Padano (Fox, 2003).   
Furthermore, it has been shown that a lysozyme-supplemented milk has a positive 
influence on the development of premature infants and can help to combat infection 
(Zimecki and Artym, 2005). Notably, indirect and direct interactions have been 
identified between the Complement system and lysozyme, whereby, the response of 
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polymorphonuclear leukocytes (PMN) chemotaxins to the Complement-derived is 
inhibited.  Lysozyme’s affinity for calcium is thought to inhibit Complement by 
chelating the divalent ions required for Complement activation (Ogundele, 1998).   
  
Antimicrobial proteins of milk fat globule membrane (MFGM)   
MFGM proteins generally that are recognised to possess antimicrobial activity are:  
• Mucin 1 (MUC1) – exhibits antiviral effects and is anti-rotavirus especially in 
neonates;  
• Mucin 15 (MUC15 or PAS III), which possesses strong antiviral properties;  
• Xanthine oxidase (XO), is a bactericidal agent that works in the gut by reducing 
oxygen;  
• Cluster of differentiation (CD36 or PAS IV), these are glycoproteins that act 
as receptors due to high sugar content.  
Glycosylyated (glyco) proteins in MFGM are believed to prevent bacterial adhesion 
to the gastrointestinal wall. MFGM fractions enriched with various (glyco) proteins, 
particularly MUC1, stimulate the production of short chain fatty acids (butyrate) and 
ammonia, as well as altering the bacterial community structure following incubation 
with colonic microbiota for 48h (Struijs et al., 2013).   Mucins play an important role 
in many biological processes, including the protection of epithelial surfaces in the 
course of immune response adhesion, inflammation, and tumour genesis.  MUC15 is 
a high molecular weight glycoprotein which may function in an antiviral capacity 
(Fong and Norris, 2009).   
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Nearly half of XO activity in cow’s milk is associated with MFGM (Charalambous, 
2012). XO, also recognised as xanthine oxidoreductase (XOR) and xanthine 
dehydrogenase (XDH), is a molybdoflavoenzyme found at high levels in bovine 
mammary epithelial cells.  Purified XO has long been known to inhibit the growth of 
bacteria such as Staphylococcus aureus, Escherichia coli and Salmonella enterides 
(Green and Pauli, 1943, Stevens et al., 2000).  It is well documented that this 
antibacterial activity is attributable to the presence of a reducing substrate such as 
hydrogen peroxide (Hancock et al., 2002).  The antibacterial activity of several MFGM 
hydrolysates against test food pathogens on agar plates prepared with M9 minimal 
media was independent of xanthine oxidase enzymatic activity (Clare et al., 2008). 
However, Clare et al. (2008) also observed antimicrobial effects by MFGM 
hydrolysates due to the generation of H2O2 by xanthine oxidase when brain heart 
infusion (BHI)-based media were used  Additional MFGM constituents like CD36 
(cluster of differentiation), an integral membrane protein, occurs in a wide range of 
cells and tissues and is recognised to play major roles in                         adhesion, signal 
transduction, and hematopathology (Greenwalt et al., 1992).  It has been demonstrated 
that CD36 facilitates adhesion and sequestration of infected erythrocytes as well as 
phagocytosis of apoptotic neutrophils and in this way may afford protection 
(Ramussen et al., 1998).    
  
  
Milk protein hydrolysates and peptides  
  
Bioinformatics tools are increasingly being used to guide the mining of potential 
antimicrobial peptides encrypted in milk protein sequences. As an example, Dziuba 
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and Dziuba (2014) identified 11 new peptides with potential antimicrobial activity 
from all peptides released during in silico proteolysis of milk proteins using 28 
enzymes.  In 2006, it was reported that protein hydrolysates generated from individual 
milk protein fractions (casein, α-lactalbumin, β-lactoglobulin, and serum albumin) 
prepared by four gastrointestinal proteinases (trypsin, α-chymotrypsin, pepsin and 
pancreatin) exhibited varying degrees of antimicrobial activity (all hydrolysates of: 
casein > α-lactalbumin > β-lactoglobulin > serum albumin > ovalbumin h) towards 24 
microbial strains tested (Biziulevičius et al., 2006).   The influence of the proteolytic 
enzyme used is also influential: tryptic hydrolysates > peptic hydrolysates > 
chymotryptic hydrolysates > pancreatic hydrolysates (Biziulevičius et al., 2006).  The 
antimicrobial effects of such protein hydrolysates adds to earlier studies and are 
consistent with the overview that mammalian body fluids containing cationic 
peptides/proteins (such as lysozyme, neutrophil-derived permeability-increasing 
peptides, defensins, etc.) are capable of killing bacteria by activating their autolytic 
enzymes, thus causing bacteriolysis (Biziulevičius et al., 2006).         
While κ-casein is a significant, highly functional fraction of milk proteins, the 
antimicrobial interest focuses on its caseinomacropeptide (CMP).  CMP is a 
heterogeneous C-terminal fragment released into whey during cheese-making as a 
result of chymosin-induced cleavage of the phenylalanine-methionine peptide bond at 
amino acid residues 105 and 106 of κ-casein. Malkoski et al. (2001) provided an early 
indication of the capacity of CMP to inhibit the growth of both Streptococcus mutans, 
Porphyromonas gingivalis and Esherichia coli.  The sialic acid content of CMP has 
been shown to be responsible for the peptide’s binding to Salmonella enteritidis and 
Enterohaemorrhagic Esherichia coli (EHEC) O157 (Nakajima et al. 2005). Using a  
Caco 2 cell line, Nakajima et al. (2005) also demonstrated that CMP  
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(Glycomacropeptide (GMP), as referred to by the authors) inhibited the adhesion of 
EHEC O157 in a dose-dependent manner, but the adhesion was not as potent when 
challenged with Salmonella infection.  Both glycosylated κ-casein glycopeptide 
(KCGP) and non-glycosylated κ-casein peptide (KCP) forms of CMP inhibited growth 
of Enterococcus faecalis in planktonic culture equally well. However, KCGP was the 
significantly better of the two at inhibiting the growth of Enterococcus faecalis (Liu et 
al. 2012).    
  
Milk oligosaccharides  
Complex carbohydrates are increasingly used in the formulation of infant milks.   
Initial interest was driven by the prebiotic potential of fructo-oligosaccharides (FOS).  
Synergistic combinations of FOS and galacto-oligosaccharides (GOS) soon followed 
which possessed antimicrobial efficacy in addition to promoting gut microbiota 
(Bruzzese, et al., 2009).  Oligosaccharides are polymers of monosaccharides, the 
prebiotic effects of which are known to promote survival of specific probiotic strains  
e.g. Bifidobacterium infantis.  Acidic, also known as sialyl-, oligosaccharides featuring 
sialic acid attachments confer additional functionality in the form of antiadhesion due 
to the stereo-specificity of their sialyl containing structures (Mehra and Kelly, 2006).  
These decoy receptors mimic epithelial cell surface glycans in order to restrict 
pathogen attachment to infant mucosal surfaces (Bode, 2012).  Bovine milk has a much 
lower concentration of sialyl oligosaccharides when compared to human milk. Given 
the prophylactic benefits of these milk-based carbohydrate structures, further research 
is needed to fully utilise these components from bovine milk (Zivkovic and Barile, 
2011). Studies have focused on chemically synthesising these structures or 
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reproducing them through bio-fermentation using genetically modified bacteria 
(Espinosa, et al., 2007).   
Clearly, milk contains a wide array of naturally occurring antimicrobial proteins. If 
these are to be fully exploited to promote human and animal health, attention must be 
devoted to fully understanding the possible inactivating effects which may occur 
during milk processing and transformation into nutritional ingredients. Such beneficial 
functionalities could be applied in a variety of applications which include, but may not 
be exclusively limited to, the reduction of mastitis in cows and improving the health 
of infants.    
  
1.5. Innate immune system  
  
Immunity refers to the ability of a host system to protect itself; the first response is the 
non-specific innate immune response, as this system fights microbes and plays a key 
role in the initialisation of the specific/adaptive immune system.  As well as 
functioning separately, some components of the innate and adaptive immune system 
components play a role in both systems (Figure 1.1).  Major constituents of the innate 
immune system include phagocytes, complement, toll-like receptors, natural killer 
cells and macrophages.  Furthermore, there are physical barriers such as skin, mucosal 
surfaces of the digestive and respiratory systems, and low pH levels in the stomach.    
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Figure 1.1 Summary of the cells of the innate and adaptive immune system (Dranoff, 2004)  
  
During early stage infection, the innate immune system is initiated and triggers an 
inflammatory reaction.  This inflammatory response at the site of infection, recruits 
macrophages, polymorphonuclear leukocytes, and mast cells through their innate 
immune receptors (Song et al., 2000).  Phagocytes engulf the microorganisms, which 
in turn may release bactericidal proteins, peptides, and enzymes, which act against 
invading microorganisms.  Complement plays a multifaceted role in the inflammatory 
response which includes coordinating different components and events.  Activation of 
the Complement system leads to the formation of anaphylatoxins C3a, C4a, and C5a 
which are reported as potent inflammatory mediators (Markiewski, 2007).  Over time, 
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the capacity of the innate immune system has evolved improving its capability to 
recognise microbial pathogens using specific identifiers which recognise invading 
organisms (Beutler, 2004).  Pattern-recognition receptors (PRRs) have a central role 
in identifying components of invading microorganisms and subsequently launch a 
response aimed at their elimination.  Inappropriate activation of PRRs can lead to 
prolonged inflammation which may be a root cause of some autoimmune and 
inflammatory diseases.  Well-reported PRRs include toll-like receptors (TLRs) and 
Ctype Lectin Receptors (CLRs), as well as cytoplasmic NOD-like receptors (NLRs).  
Thus, these components are regulated by the degradation or translocation of the innate 
receptors themselves and through the involvement of intracellular regulators or 
amplifiers (Cao, 2016).    
  
Milk produced by a healthy bovine udder should contain relatively low numbers of 
somatic cells (monitored by somatic cell counts (SCC)) and, thus, reflect low levels of 
inflammation.  Milk somatic cells consist of a number of different cell types; 
neutrophils, macrophages, lymphocytes, and epithelial cells.  In self-limiting mastitis, 
bacteria are eliminated after the initial inflammatory phase, neutrophil recruitment 
ceases and SCC returns to healthy (low) levels.  Prolonged infection invokes the 
production of more specific immune components and also has implications for milk 
yield and the quality (Ogola et al., 2007, Riollet et al., 2002)  
  
1.6.Complement system  
  
Complement, as a fundamental part of the innate immune system, was originally 
identified by Jules Bordet in 1899 as a component of the plasma that enhances the 
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opsonisation and bactericidal effects of antibodies.  The Complement system delivers 
a rapid and proficient means to protect the host from invading microbes.  Due to its 
diverse biological activities, Complement is a central component in inflammation, a 
natural response of the host tissue to any injury.  There is also increasing evidence that 
Complement significantly contributes to the regulation of the adaptive immune 
response (Kirschfink, 1997).  Complement consists of a group of more than 30 plasma 
proteins, the main function of which are the recognition and elimination of invading 
microbes.  Complement can be triggered either by a target-bound antibody (the 
classical pathway), recognition of microbial polysaccharide structures (the lectin 
pathway) or recognition of other foreign surface structures as yet uncharacterized (the 
alternative or properdin pathway) (Kuby, 1997).  Once activated, it progresses in a 
cascading movement, whereby the activation and production of one protein induces 
the next, which in turn produces the next required protein and so on (Rainard and 
Riollet, 2003).  By acting in a sequential cascading action, the Complement system 
stimulates a plethora of physiological responses.  All three activation pathways share 
the common step of activating the component C3, but differ in their mechanisms of 
recognition.  Complement plays a vital role in phagocytosis as part of the innate 
immune response and is also important in initiation and control of the inflammatory 
response (Barrio et al., 2003).  Three distinct aforementioned physiological pathways, 
classical, alternative and the mannan binding or lectin pathway (Fig 1.2).  While 
initiated in different ways, all converge at the C3 convertase activation stage of the 
cascade.  The classical pathway is initiated by the binding of antigen-antibody 
complexes as well as due to presence of particular microbes.  The mannan binding 
lectin (MBL) pathway may be activated by the recognition and binding of PAMPs by 
lectin proteins (Holmskov et al., 1996).  Thus far, three members of this pathway have 
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been identified: MBL15, ficolin H and ficolin L16 (Carroll, 2004).  The lectin pathway 
is a member of the collectin family of proteins.    
  
Furthermore, the Complement system may be stimulated in the absence of antibodies 
as a fundamental component of the innate immune system (Kuby, 1997).  The 
alternative pathway may be activated in circumstances where antibodies are not 
required, in which case a spontaneous conformational change of C3 provokes 
formation of an enzyme complex that cleaves further molecules in the cascade and sets 
in motion an amplification reaction that activates the complement (Zipfel and Skerka, 
2008).  The alternative pathway may be stimulated by specific bacterial cell membrane 
components, i.e., lipopolysaccharides.  This pathway differs from the other two in that 
it is always ‘turned on’ because of the spontaneous activation of C3 and its ability to 
bind to a range of acceptor sites.  During studies of the alternative immune system, it 
has been found that classical pathway is less active due to a shortage of component 
C1q (Rainard, 2003).  The degradation of Complement component C3 into C3b and 
C3bi due to the ability of Factor I and Factor H confirms that the alternative pathway 
is active (Pangburn and Müller-Eberhard, 1984).  This pathway is triggered by a 
spontaneous conformational change of C3, which provokes formation of an enzyme 
complex that cleaves further molecules in the cascade and sets in motion an 
amplification reaction (Zipfel and Skerka, 2008).  The manner by which Complement 
proteins migrate into milk is still a matter of speculation.   
The importance of the presence of the Complement system in HBM and mastitic 
bovine milk has been previously reported (Rainard and Riollet, 2006, Ogundele, 
2000).  Typically, it was thought that the levels of Complement in healthy bovine milk 
was not sufficient for chemotaxis or opsonisation; thus, the consensus has been that 
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the biological significance of the Complement was low (Rainard and Riollet, 2006, 
Rainard, 2003).  It is also speculated that there may be some synergism when the 
antimicrobial effects of MFGM and Complement in human milk are combined 
(Ogundele, 1999a).   
 
Figure 1.2 Illustration of the three Complement pathways – Classic, Alternative and MBL  
pathways (Janeway et al, 2005).  
  
1.7.Mastitis  
  
Currently the dairy food sector is one of Ireland's most important indigenous 
manufacturing divisions.  With 85% of all dairy output exported, Ireland is ranked the 
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10th largest dairy export nation in the world.  In 2013, export values for Irish dairy 
product and ingredients exceeded €3 billion. The strongest performing product 
categories were butter, cheese, infant formula, skim milk powder, whole milk powder 
and whey protein ingredients.  Mastitis in dairy herds is a common occurrence which 
impacts on production cost and out-turns on dairy farms.  Further losses may be due 
to the effect on milk quality, treatment costs as well as animal replacement (Whist and 
Østerås, 2007).  Milk yield losses of approx. 100-150 kg milk/cow/lactation can also 
result (Erb et al., 1985, Seegers et al., 2003).  In 2013, mastitis was estimated to have 
caused Irish farmers a net farm profit decrease of €19,504 for a 40 hectare farm as 
SCC increased from <100,000 cells/ml to >400,000 cells/ml (ICBF).  Several studies 
have found relatively large associations between mastitis and fertility, thus, it can have 
an even greater cost for dairy farmers (Loeffler et al., 1999).  Mastitis can be a 
persistent inflammatory response and in extreme cases can be potentially fatal.  SCC 
is a useful secondary indicator of mastitis, it is used in quality control programmes to 
assist with reduction in the incidence of mastitis (Mrode and Swanson, 2003).   
  
Bacterial mastitis pathogens have been loosely classified as either environmental or 
contagious pathogens.  Contagious pathogens are a sub-group of bacteria which have 
adapted to survive within the host, and can be indicators of the presence of 
intramammary infections in the herd (Riekerink et al., 2006).  Mastitis is mainly caused 
by bacterial infection - the more well-known infective strains include Streptococcus 
agalactiae (Str. agalactiae), Staphylococcus aureus (S. aureus), Mycoplasma, Strep. 
Dysgalactiae (Str. dysgalactiae), Streptococcus uberis (Str. uberis), Pseudomonas 
spp, Prototheca and yeasts.  Inflammation triggered by a gram-positive bacterium Str. 
agalactiae blocks mammary ducts, leading to decreased milk production, increased 
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SCC and eventual involution. S. aureus has been identified in a number of cases of 
mastitis where it causes per-acute, acute, chronic, and subclinical mastitis.  A further 
issue with this contagious form of mastitis is that some strains are antibiotic-resistant 
(Tenhagen et al., 2006).  Another causative species of bacteria is Prototheca, which 
survive in muddy soil conditions and can induce chronic cases of mastitis; Prototheca 
infections are typically associated with cases of environmental mastitis (Costa et al.,  
1998).  Finally, coliform-induced mastitis is usually caused by gram negative  
Esherichia coli (E. coli), Klebsiella spp., Enterobacter spp., and Citrobacter spp (Smith et 
al., 1985).   
  
Consequently, stringent hygiene practices in milking parlours, including clean 
bedding, clean housing and sanitisation of equipment and teat-dipping, are advised.  
Many countries including UK, Germany and Finland, which have succeeded in 
reducing the incidence of subclinical mastitis through good hygienic practices have 
also reduced the prevalence of the main mastitis causing pathogen (Pitkälä et al., 
2004).    
  
  
  
  
1.8.Assaying the bacteriostatic/bactericidal effects of milk    
  
Milk has long been recognised to resist infection; originally the bacteriostatic qualities 
of milk were reported by Hanssen in (1924) who speculated that the presence of 
oxidising enzymes had bactericidal properties.  Moreover, lactoferrin and IgA in milk 
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have been identified to contribute to protection.  However, it has been determined that 
serum proteins, specifically Complement, are lethal to some specific gram negative 
bacteria (Taylor, 1983).   Exploiting this knowledge, a more specific assay was 
customised to test milk samples; a bactericidal sequestration assay was developed in 
1975 to help with the identification of the bactericidal and haemolytic activity, which 
more recently has been used to assess the Complement activity of human milk samples 
(Brock et al., 1974; Ogundele, 2001).  Brock et al reported further evidence of the 
bactericidal effects of milk and colostrum but did not differentiate whether it was due 
to Complement-mediated response or the activity of immunoglobulins (IgG, IgM) in 
milk, or both.  The background of this assay is based on a reported conformation 
change in serum-sensitive bacteria, whereby increased sensitivity to bactericidal action 
is noted.  This structural change involves the loss of lipopolysaccharide as well as other 
characteristics, and thus, may provide some explanations as to why the group of 
bacteria with the O- antigen are more susceptible to this (Rowley, 1968).  The 
bactericidal sequestration assay established in this study utilises the knowledge that 
gram-negative bacteria (e.g. E. coli) are sensitive to complement lytic action.      
  
  
  
1.9. Escherichia coli O111   
  
Escherichia coli (E. coli) is a well-recognised gram negative bacterium which is 
commonly found in intestinal flora of warm blooded organisms.  The rod shaped 
bacterium is characterised as a facultative anaerobe (Olsvik et al., 1991).  E. coli is one 
of the most extensively studied prokaryotic model organisms that plays a major role 
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in biotechnology and microbiology.  Furthermore, it is a major species among the 
facultative anaerobic normal flora of the intestine and plays an important role in 
maintaining intestinal physiology.   E. coli O111 was originally discovered in 1945 
and was isolated from a faecal sample of gastroenteritis; it has also been associated 
with neonatal diarrhoea in infants (Reiter and Brock, 1975, Coleman et al., 1977).  It 
has since been found in other sources, i.e., bovine mastitis, chicken faeces, piglet 
enteritis, as well as cats, dogs and kittens (Taylor 1961).  It was one of the first strains 
implicated in cases of gastroenteritis in the 1940s, and has been classified as a classic 
serogroups of enteropathogenic E. coli (EPEC).  EPEC’s are often responsible for 
infantile GI infections, thus, antibodies against these bacteria play a significant part of 
the protection in human milk (Marcy, 1976, Mietens, et al, 1975).  E. coli O111 has 
been implicated in numerous outbreaks of enteric disease, including relapsing 
diarrheal illness and in a community outbreak of diarrhoea in Finland (Campos et al., 
1994).    
The E. coli O111 strain has been identified to be susceptible to Complement activity, 
it has been considered that the co-evolution of  bacteria with complement systems for 
millions of years, allowed some specific microorganisms to develop the ability to 
inhibit the activation of complement pathways.    
  
1.10.  Effect of cow breed on milk composition  
  
Domesticated cattle play an important role in modern farming and contribute to global 
populations nutritional requirements through milk, meat ingredients and by-products.  
Cattle have long been farmed, and different breeds have evolved due to the influence 
of man and the evolutionary effects of climate, disease and geographic separation 
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(Blott et al., 1998).  Cattle genetics have been monitored since the eighteenth century 
by considering physical appearances such as horn morphology and coat colouring in 
the course of adapting breeds for domestication and commercial purposes.  There are 
two taxa of cattle; zebu (Bos indicus) and taurine (Bos taurus) (MacHugh et al., 1997); 
in total, there 790 breeds of cattle have been identified and, of this, approximately 270 
breeds are native to Europe (Blott et al., 1998).  The major distinctions which separate 
the two taxa of domestic cattle are the presence of a hump, large dewlap, skin anatomy, 
and physiological characteristics that involve adaptation to arid conditions (Bradley et 
al., 1998).  Recent studies have used mitochondrial DNA to investigate the sequence 
diversity of cattle populations; analysis of mtDNA displacement loop sequences have 
indicated that the two main domestic cattle species have distinct haplotype profiles 
(Hristov et al., 2015).  There have been reports that inherited traits may play a 
significant role in host immunity, bovine lymphocyte antigen (BoLA) alleles are 
associated with disease incidence, i.e., class I and class II BoLA genes have been 
associated with the incidence of mastitis, bovine leukaemia virus infection, chronic 
posterior spinal paresis, and total parasitic load (Dietz et al., 1997).        
  
Cattle genetics and breeding may be utilised in the course of selecting for increased 
resistance to clinical mastitis, while until now indirect selection has been practiced 
widely by monitoring SCCs.  It has been suggested that the bacteriolytic enzyme 
lysozyme may be used as an index of macrophage functional status; in this way, the  
Lyz gene is suggested as a candidate marker for improvement of mastitis resistance 
(Chen et al., 2013).    
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1.11. Concluding remarks  
The review of literature in this Chapter has focussed largely on profiling the protective 
effects of components in bovine milk.  In contrast to HBM, there is a paucity of 
information relating to the transfer of immune components to the milk and, indeed, the 
comparability between the biological efficacy of such components contributed by the 
human and bovine. Formula-fed infants would appear to be at a disadvantage 
compared to their breast-fed counterparts as continuing efforts at the ‘humanisation’ 
of bovine milk to date have stopped short of addressing such a gap.  Thus, it is 
becoming an area of great interest for the dairy sector, and there is a need to improve 
the health benefits and functionality of infant formulas.  To begin with, it is important 
to understand more about the extent to which Complement as a major innate immune 
component occurs in bovine milk and how well it compares with that of HBM.  It is 
also of interest to understand whether Complement in bovine milk associates with 
MFGM.  Thus, in the following Chapter, an initial assessment of Complement activity 
in freshly drawn bovine milk is explored.    
  
  
  
1.12. Thesis Objectives  
  
1. In the absence of established data about the presence and activity of 
Complement in bovine milk, it was firstly necessary to set up the appropriate 
analytical methodology and a milk sample collection plan to monitor  
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Complement activity in milk.  
  
2. To study the effects of heat treatment and cream separation, by simulating the 
effects of industrial dairy manufacturing processes.   
  
3. To explore the possible association between Complement and milk fat globule 
membrane.  
  
4. To evaluate an improvement of the bacterial sequestration assay for monitoring 
of Complement using a biotechnological adaptation to confer fluorescence 
functionality to the Complement-sensitive target organism.  
  
5. Evaluate differences in Complement activity between the infected and healthy 
quarters of lactating dairy cows during induced mastitis in udder quarters.  
  
6. To monitor the contribution of dairy breed to Complement activity in milk by 
milk sampling from purebred and cross-bred herds of commercially important 
milking breeds  
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Chapter II Detection and characterisation of Complement protein activity in 
bovine milk by bactericidal sequestration assay  
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Detection and characterisation of Complement protein activity in bovine milk by bactericidal 
sequestration assay. Journal of Dairy Research, 82(3), pp. 328-333.  
2.1. Abstract   
  
While the Complement protein system in human milk is well characterised, there is 
little information on its presence and activity in bovine milk.  Complement forms part 
of the innate immune system, hence the importance of its contribution during milk 
ingestion to the overall defences of the neonate.  A bactericidal sequestration assay, 
featuring a Complement sensitive strain, E. coli O111, originally used to characterise 
Complement activity in human milk, was successfully applied to freshly drawn bovine 
milk samples.  Consequently, Complement activities in both human and bovine milks 
were compared.  Although not identical in response, the levels of Complement activity 
in bovine milk were found to be closely comparable with that of human milk.  
Differential counts of E. coli O111 derived from the initial and final CFU after the 2h 
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incubation were 6.20 and 6.04 log CFU/ml for raw bovine and human milks, 
respectively, the lower value representing a stronger Complement response.  
  
Exposing bovine milk to a range of thermal treatments, e.g., 42°C, 45°C, 65°C, 72°C, 
85°C or ≥ 95°C for 10 min, progressively inhibited Complement activity with 
increasing temperature, thus confirming the heat-labile nature of this immune protein 
system.  Low level Complement activity was found, however, in samples heat-treated 
in 65°C or 72°C and in retailed pasteurised milk, which highlights the limit to which 
high temperature, short time (HTST) industrial thermal processes should be applied if 
retention of activity is a priority.  Concentration of Complement in the fat phase was 
evident following cream separation, and this was also reflected in the further loss of 
activity recorded in low fat variants of retailed pasteurised milk.  Laboratory-based 
churning of the cream during simulated butter making generated an aqueous 
(buttermilk) phase with higher levels of Complement activity than the fat phase, thus 
pointing to a likely association with the milk fat globule membrane (MFGM) layer.   
  
2.2. Introduction  
  
As well as being a source of essential nutrients for optimum growth and development, 
milk provides the neonate with protective elements to support survival of the newborn 
(Van Hooijdonk et al., 2000, Hanssen, 1924).  While the bacteriostatic qualities of 
milk were recognised as far back as 1924 (Hanssen, 1924), research over the years has 
focussed on the characterisation of its antimicrobial components, such as lactoferrin, 
lactoperoxidase, lysozyme, peptides derived in vivo during digestion, and sialyl-
containing oligosaccharides.  However, less consideration appears to have been given 
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to the role of another line of defence, i.e., the extent to which the innate immune system 
of the lactating mammal is manifested in its milk secretions.  Innate immunity with its 
physical barriers and cellular components provides non-specific protection as a first 
line of defence (Ricklin and Lambris, 2007), which is distinguishable from that of the 
adaptive immune system that typically responds to specific pathogenic challenge 
(Galyean et al., 1999).  Within innate immunity, Complement consists of serum and 
membrane proteins which circulate as inactive precursors in the blood system.  The 
triggering of these precursors initiates a cascade of protein cleavages which culminates 
in the amplification of a cell-killing membrane attack complex (Oviedo-Boyso et al., 
2007).  Though initiated by different mechanisms, all three established Complement 
pathways, i.e., the classical, alternative and mannan-binding lectin (MBL) converge at 
the point when complement component C3 becomes active  
(Abbas et al., 1994).  The classical pathway commences with immune complexation 
by IgG or IgM to pathogens or foreign antigens, while the alternative pathway is 
triggered by either carbohydrates, lipids or proteins found on the surface of foreign 
microbes or cells in the body, and the MBL pathway is activated when either MBL or  
Ficolin binds to the surface of pathogens due to carbohydrate moieties (Sarma and  
Ward, 2011).       
  
Efforts to date at addressing the presence and role of Complement in human milk 
(Ogundele, 2001) also lend support to the view that such innate immune components 
migrate from the circulatory system in the mammary gland into the secreted milk.  
However, little is known about its activity in bovine milk and its presence is not even 
recognised in the recent revision (6th) of the nomenclature of the proteins in cows’ 
(Farrell et al., 2004).  A lack of suitable assays may have been a contributing factor to 
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this paucity of information.  Gradually, the bactericidal sequestration assay-based 
analytical approach was adapted initially to help identify bactericidal and haemolytic 
activity of bovine colostrum (Reiter and Brock, 1975), bovine mastitic milk (Rainard 
P, 1984) and human milk (Ogundele, 2001).  The uniqueness of the bactericidal 
sequestration assay in this case is that growth of a specific pathogenic bacterial strain, 
i.e., E. coli O111 is sensitive to the presence of Complement, thus allowing the extent 
of growth inactivation to be used as an indirect measure of Complement activity 
present.   
  
Thus, an objective of this study was to adapt and apply the bactericidal sequestration 
assay used by Ogundele (2002) to establish the level of Complement activity in fresh 
bovine milk and its comparability with that of human breast milk.  A further objective 
was to evaluate the extent to which such activity may be affected by typical milk 
processes such as heating and cream separation.  This interest was taking place against 
a backdrop of where advances in the ‘humanisation’ of bovine milk for use as infant 
feed formula requires a deeper understanding of the biological comparability between 
both bovine and human breast milk Complement, so that appropriate strategies may 
be designed for its protection in freshly secreted bovine milk during the course of dairy 
manufacturing processes.   
  
2.3.Material and Methods  
  
2.3.1 Sample preparation - Milk samples  
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Fresh whole bulk bovine milk was collected from the Moorepark Dairy Production 
Centre (MDPC) farm on three consecutive days.  The SCC of the freshly collected 
milk was determined using Bentley Somacount 300® (Bentley Instruments Inc.,  
Chaska MN, USA), SCC’s of <200,000 cells per ml was required for use of the milk.   
On three consecutive mornings fresh commercial products including cream, full fat 
milk and low fat milk were purchased from local supermarkets and tested directly.  
  
Human milk was collected from the Western Health and Social Care Trust (Glenshane 
Road, Londonderry BT47 6SB, United Kingdom) and was stored in aliquots at -80°C 
until required.  The samples were slowly thawed at 4°C overnight before analysis.    
  
  
2.3.2 Control preparation  
  
Freshly collected raw milk was heat treated at 56°C for 30 min to ensure complete 
inactivation of the complement protein (Korhonen et al., 2000).  All samples were 
screened using the ISO methods (ISO, 2013, ISO, 2004) and also the milks were 
streaked on Nutrient and Luria Bertani agar.    
  
2.3.3 Effect of heat treatment  
  
Individual milk samples were exposed to a range of temperatures: 42°C, 45°C, 65°C, 
72°C, 85°C and 95°C with 10 min holding time before bactericidal sequestration assay 
in order to determine the effect of heating on Complement activity.  (Korhonen et al., 
2000).  Milk samples were heat-treated using Hettich Elbanton special products oil 
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bath (Hettich Benelux B.V., De Aaldor 9 – 4191 PC Geldermalsen, Netherlands) with 
rocking arm to ensure uniform heat treatment throughout the samples. A control 
sample was produced by heating milk at 56 C for 30 min and was a reference for 
complete Complement inactivation.  
  
2.3.4 Milk samples separation and washing       
  
An Armfield disc bowl centrifuge (Armfield, Ringwood, UK) was used to generate 
cream samples (approximately 40% fat) and skimmed milk (approximately 1% fat) 
from the fresh raw milk.  The cream was then stored at 4°C overnight and the following 
morning a Kenwood Chef food mixer (Model KM220, Harvant, Hants, UK) was used 
to disrupt the cream emulsion resulting in the production of butter.  From this, 
buttermilk was released and was filtered through glass wool to remove butter grains.  
Human milk was thawed overnight at 4°C; this was then separated by centrifugation 
at 5000 rpm for 15 min at 4°C (Patton and Huston, 1986) in order to separate the fat 
fraction.    
  
Washed buttermilk was prepared using the Armfield disc bowl centrifuge; however, 
an additional step was incorporated whereby the cream was suspended in sterile 
distilled water and held at 37°C for 1h to wash the buttermilk.  The separation 
procedure was repeated (Armfield disc bowl centrifuge) and cream collected.  This 
step was repeated twice more.   
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2.3.5 Bacterial Strain  
  
E. coli O111 (E. coli NCTC 8007, serotype O111 K58(B4)) a pathogenic Complement 
sensitive strain was purchased from Health Protection Agency Culture Collections  
(Health Protection Agency Culture Collections Porton Down Salisbury Wiltshire, SP4 
0JG UK).  This strain was routinely grown in Luria-Bertani (LB) medium at 37°C with 
shaking. Standard LB broth and agar was prepared as described by Sambrook et al.  
(2001).   
  
  
  
2.3.6 Bactericidal sequestration assay   
  
E. coli O111 was prepared for overnight growth at 37°C on LB agar.  An isolated 
colony from replicate plates was inoculated into 3 tubes of LB broth (Merck KGaA, 
Darmstadt, Germany) and grown over night at 37°C.  The overnight cultures were 
centrifuged at 5000 rpm, a pellet was formed, the supernatant was removed and the 
pellet was re-suspended in phosphate buffer saline solution (1 x PBS solution); this 
step was repeated twice.  At the final step, the pellet was suspended in LB broth and 
adjusted to 3 x 108 colony forming units (CFU) per ml using the McFarland Method 
(Goldman et al., 1986).  Using 96-well plates, 3 x 20 µl of each of the three replicate 
cultures was added to each round bottomed well (SARSTEDT Ltd, Wexford, Ireland) 
and 80 µl of the sample to be tested was then added.   The plate was incubated at 37°C 
for 2h shaking at 200 rpm (Model Mini 4450 SHKA4450-1CE, Fischer Scientific, 
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Ballycoolin, Dublin).  A 20 µl sample was taken from each well after the incubation 
time, and total viable counts were enumerated on LB agar using the pour plate method.    
              
2.3.7 Serum susceptibility assay   
  
The blood serum susceptibility assay developed by Hogan et al., (1989) was adapted 
by substituting blood with milk.  Approximately 125 µl of freshly collected bovine 
milk and heat treated milk (control) were added to individual wells of a 96-well plate, 
also 100 µl Tris-NaCl buffer was added (1x Sigma Chemical Company, St. Louis, 
MO).  The next step was the addition of 25 μl of the E. coli O111 inoculum, which had 
been grown to a level of 106 CFU per ml.  The 96-well plate was incubated at  
37°C and viability of the bacteria evaluated at 0 and 4h.    The viable bacteria were 
plated on LB agar (Merck KGaA, Darmstadt, Germany) for 15h at 37°C, results were 
collected and the differential growth of the strain from the serum susceptibility assay 
was presented by subtracting the initial amount of colonies (0h) from the final 
number of viable colonies (4h).        
  
2.4. Results  
  
2.4.1. Comparison of Complement-associated bactericidal sequestration activity 
of bovine and human milks  
  
The sequestration assay used relies on the specific sensitivity of E. coli O111 to the 
presence of Complement; thus, an active Complement system in milk would be 
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expected to restrict growth of the strain.  Furthermore, since Complement is known to 
be inactivated at temperatures >56°C for 30 min (Korhonen et al., 2000) it is thus 
possible to compare growth of E. coli  O111 in heated and raw milk, the difference in 
growth rates between the heated (control) and raw milks being attributable to 
Complement activity.  This was evident when comparing the growth of E. coli in 
heattreated (56°C, 30 min) milk, freshly collected raw bovine milk and human milk 
(Fig. 2.1) where differential counts after 2h incubation at 37°C were 6.32, 6.20 and 
6.06  viable colonies of E. coli O111 (log CFU/ml), respectively, the lower value 
indicating a more effective Complement response.    
  
 
  
Figure 2.1  Differential reduction of E. coli O111 (log10 CFU/ml) during bactericidal 
sequestration assay of  heated bovine milk (control), raw bovine milk and human milk,  
following inoculation and incubation for 2h incubation at 37°C.  
This corresponded to cell reduction factors of 0.12 and 0.26 following incubation with 
raw bovine milk and human milk respectively. Following analysis for normality, it was 
determined that a Kruskal-Wallis test should be applied to the differential data, the 
results of which confirmed that there was a statistical difference (p < 0.01) between all 
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three samples, which was supported further by a Mann-Whitney test to show that both 
raw bovine milk and human milk were significantly different (p < 0.01) from the 
control (heat-treated milk).  
  
2.4.2. Growth characteristics of E. coli O111   
  
The growth characteristics of E. coli O111 was compared by incubating the strain 
separately in LB broth or bovine milk overnight at 37°C in order to have an improved 
understanding of its vitality during deployment in the bactericidal sequestration assay.    
The E. coli O111 strain grew steadily on LB agar starting from an initial viable colony 
count of 7.18 to reach ~8.98 log CFU/ml after 24h incubation (Fig. 2.2). Growth of the 
strain in bovine milk peaked at 8.51 log CFU/ml at 13h during the same period, after 
which it declined slightly.    
Complement activity was also evident when E. coli was inhibited in untreated wells 
during a serum susceptibility assay of forewarmed (56°C, 30 min) and non-heated 
bovine milk. The plated viable colonies reached peak growth of 8.0 and 8.95 log 
cells/ml after incubation with the raw bovine and heated bovine milks (control), 
respectively (p < 0.05).    
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Figure 2.2. Total viable counts of E. coli O111 (log10 CFU/ml) during incubation at 37°C  
for 24h in LB broth and bovine milk.  
  
  
2.4.3. Investigation of Complement activity in low fat bovine milk  
  
Preliminary laboratory work carried out on the variation between freshly collected 
bovine milk and in-store purchased full-fat milk was extended to include low-fat (1% 
fat) retail milks and skim milk prepared by cream separation in the laboratory from 
freshly collected raw bovine milk (Fig. 2.3). Subsequent to assessment for normality, 
a Kruskal-Wallis test revealed that there was a statistically significant difference (p < 
0.001) in colony forming units across the five groups [control (heat inactivated milk), 
raw milk, retail full-fat milk, skim milk, retail low-fat milk].  The raw untreated bovine 
milk was more effective in inhibiting growth of E. coli O111 than the pasteurised 
sample.  The lower-fat milk variants (in-store purchased and lab-prepared) were also 
less effective in reducing growth of the Complement-sensitive strain.  Further 
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statistical analysis, which examined individual groups (Mann-Whitney test), 
confirmed that full fat raw milk was significantly different from all other samples (p < 
0.01).     
 
  
Figure 2.3 Total viable counts of E. coli O111 (log10 CFU/ml) after 2h following 
incubation with heated bovine milk (control), raw bovine milk, retail pasteurised milk, raw 
bovine skim milk and retail pasteurised low fat milk during the bactericidal sequestration 
assay maintained at 37°C.  
2.4.4. Effect of fat reduction in human milk  
  
Laboratory centrifugation (Patton and Huston, 1986) was used to defat (remove the 
upper cream layer) human milk since the available volume was too small for treatment 
by conventional dairy cream separation technology.  
Similar to bovine milk, the full-fat form of human milk was significantly (p < 0.05) 
more effective than the defatted/skimmed human milk (Fig. 2.4), thus confirming the 
association between Complement and the fat phase of the milks of both species at a 
microstructure level.   
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Figure 2.4 Total viable counts of E. coli O111 (log10 CFU/ml) after 2h incubation in (i) 
heat treated bovine milk (control), (ii) lab prepared skim human breast milk, (iii) human  
breast milk, in accordance with the bactericidal sequestration assay.  
2.4.5. Effect of heat treatment on Complement activity  
  
The bactericidal sequestration assay was performed on bovine milks which had been 
heated to each of the following temperatures: 42°C, 45°C, 65°C, 72°C, 85°C or 95°C 
with holding for 10 min and compared to that of  bovine milk heated to 56°C for 30 
min as control (Fig. 2.5).  Optimum Complement activity (6.52 log CFU/ml) was 
observed at 42°C followed by a slight loss (6.76 log CFU/ml) as the temperature 
increased to 45°C.  Based on assay counts of 7.83 - 7.92 log CFU/ml, a sizeable loss 
in Complement activity occurred when these milks were heated to either 65°C or 72°C 
for 10 min (Fig. 2.5).  At the same time, the residual Complement activity associated 
with the latter two temperatures, which correspond to batch pasteurisation (65°C, 30 
min) and continuous high temperature, short time (HTST) holding conditions (72°C, 
15 s), is consistent with its low level in retail, commercially pasteurised milks referred 
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to earlier. Further increases in temperature (85°C or 95°C for 10 min) increased the 
levels of inactivation of the Complement activity. All samples were significantly 
different from one another χ2 (6, n=21) = 28.566, p < 0.001 (Fig.  2.5).  Further posthoc 
comparisons using the Mann-Whitney test to look at individual samples identified that 
there was no significant difference between heating 65°C and 72°C (p < 0.05).  
 
Control 42 45 65 72 85 95 
Temperature (°C) 
  
Figure 2.5 Total viable counts of E. coli O111 following 2h incubation in accordance with  
bactericidal sequestration assay  for 2h, 37°C.  
2.4.6. Comparison of cream and buttermilk samples  
  
Buttermilk is known to be rich in milk fat globule membrane (MFGM) components 
(El-Loly, 2011).  The Complement activity of buttermilks was significantly (p < 0.05)  
greater than that of the creams from which they were generated according to the  
Kruskal Wallis test (Fig. 2.6). The  buttermilk prepared from the cream of raw milk  
was significantly different (p < 0.01) from the laboratory-prepared cream, retail cream 
and the washed buttermilk samples based on the Mann-Whitney test of comparing each 
group individually A loss of bactericidal sequestration activity in the buttermilks 
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generated from washed cream would suggest that Complement components were 
removed to some extent into the aqueous phase.  
 
  
Figure 2.6 Total viable counts of E. coli O111 (log10 CFU/ml) following 2h  incubation in  
(i) heated bovine milk, 56°C, 30 min (control), (ii) cream (~40% fat) prepared from freshly 
collected raw bovine milk, (iii) retail pasteurised cream, (iv) lab prepared buttermilk from 
cream of raw milk, and  (v) lab prepared buttermilk made from thecream (washed twice at 
37°C for 1h) of raw milk, after 2h incubation at 37°C according to the a bactericidal  
sequestration assay.  
2.5. Discussion  
  
This study confirms that Ogundele’s (2002) bactericidal sequestration assay, which 
uses a specific strain of E. coli to detect the presence of Complement activity in human 
milk, may now be extended for similar assay detection in bovine milk.  The 
bactericidal sequestration assay confirmed the presence and activity of Complement 
in bovine milk, which also suggests that both human and bovine milks are broadly 
analogous in terms of their sequestration response (Fig. 2.1 and Fig. 2.4).   This is an 
interesting finding given the complexity of Complement, with its 30+ proteins and 
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protein fragments, i.e., that there should be considerable homology between human 
and bovine milks. Thus, the milks of both species would appear to share the same 
amplifying Complement cascade that builds up to the activation of a cell-killing 
membrane attack complex (Ogundele, 2001).    
  
The results in Fig. 2.1 also highlight that the bactericidal sequestration assay was 
adaptable to allow for the direct comparison of human and bovine milk, thus making 
it possible to further investigate various bovine milk by-product streams and also milks 
subjected to different processing treatments.   
Exposure to a range of thermal treatments of 42°C, 45°C, 65°C, 72°C, 85°C and 95°C 
for 10 min progressively inhibited Complement activity (Fig 2.5).  The initial loss in 
Complement activity over the course of a 3°C rise during heating of bovine milk from  
42 to 45°C highlights how heat labile these immune proteins are. Some residual 
Complement activity is still detectable in and around typical milk pasteurisation 
temperatures whether by batch heating or HTST methods.  This concurred also with 
assay results generated with samples of commercially retailed pasteurised milks.   
Testing of fresh untreated and retail pasteurised bovine milks in both full and low fat 
variants provided the first indication that Complement activity appeared to be greater 
in milks containing a higher fat content (Fig. 2.3). This was confirmed in the course of 
a follow-up study involving cream separation of milk by either gravity-induced or 
centrifugally-employed methods, which showed that greater Complement activity was 
detectable in the fat-enriched phase of both bovine and human milk.  Attempts at cream 
dilution to ascertain if there was a relationship between Complement response and fat 
content were not conclusive. This may have been due to limitations with the 
microbiological assay, as a prozone-based inhibition effect has previously been 
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described (Rainard, 1984, Ogundele, 2001).  The prozone effect, originally described 
by Neisser-Wechsberg (1901), describes the inhibition due to excess antiserum of the 
bactericidal reaction which is mediated by the complement system.  This inhibition by 
excess antiserum may occur when the normal serum serving as a Complement source 
is either lacking in bactericidal activity itself or is only capable of limited activity due 
to the presence of specific antibodies (Muschel et al., 1969).  As cream may contain 
more concentrated levels of antisera, in particular high concentrations of IgG, they 
may mask the bactericidal effect of cream.  In any case, Complement-based 
sequestration of E. coli O111 was no longer observed in samples in which milk fat was 
depleted or substantially reduced in the case of raw and retail low-fat milks. Simulated 
butter-making of the prepared creams enabled Complement activity to be tracked 
during further partitioning between the fat and aqueous (buttermilk) phases. Potent 
Complement activity evident in buttermilk samples suggests that it most likely 
associates with the MFGM components present. MFGM, has already been shown to 
exhibit some antibacterial properties (Singh, 2006).  MFGM as a tri-layer of both 
proteins and lipids from the endoplasmic reticulum membrane and mammary 
epithelium cells that envelopes the lipids in milk (Mather, 1999), is also a carrier of 
biologically active molecules like phospholipids, sphingolipids, cholesterol and other 
bio-functional proteins e.g. xanthine oxidase (Lopez 2011, 2012).  
  
Overall, it can be seen that the Complement system is present in bovine milk and, 
while heat labile, a certain amount of activity was detectable after milk pasteurisation. 
Although not identical in response, the levels of Complement activity in bovine milk 
are comparable to that of human milk.  Complement’s association with the fat phase 
of milk has implications for the development of low fat variants of fresh dairy products, 
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and indeed where milk fat is replaced by non-dairy fat sources in infant formula.  
Future studies should aim to further investigate the factors that influence Complement 
activity in bovine milk and methods to retain its activity during processing.  
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Chapter III  
  
Establishment of a relationship between globular milk fat and active Complement  
proteins  
  
  
  
  
  
  
  
  
  
3.1. Abstract  
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Recent work by the authors has identified the presence of Complement proteins in 
bovine milk; furthermore, an association between active Complement and the fat 
fraction has also been recognised.  These findings pointed us to study the linkage 
further, such that the level of association between the milk fat separation and the 
Complement activity could be quantified.  Thus, the present study encompasses the 
development of a novel method for the fractionation of bovine milk; this new 
technique restricts the levels of damage or interference to the natural activities and 
composition of the milk sections.  Milk was systematically collected from each section 
of a graduated cylinder using a sterile syringe over a 24h period.  Following this, each 
sample was assessed for fat content, somatic cell counts, fat globule size and total 
bacteria counts.  The somatic cells and bacteria rose to the top of the milk, along with 
the fat; the average fat globule size (FGS) started initially in between 3.28 μm – 3.91 
μm and increased over 24h to a wider range of 7.28 μm -2.54 μm.  Next, the fractions 
collected throughout the 24h study were tested with a bacterial sequestration assay and 
it was determined that, as fat content increased, the sequestration capacity of the 
fractions also increased, which appeared to confirm the relationship between 
complement activity and fat content.  
  
3.2. Introduction  
  
Milk is basically an oil-in-water emulsion; milk fat globules are stabilised by a 
naturally occurring membrane that functions both as an emulsifier and biological 
transporter, i.e., a milk fat globule membrane (MFGM) formed during milk secretion 
in the mammary gland.   
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The natural creaming process in milk occurs when larger sized milk fat globules rise 
to the surface. Such gravity-based separation was traditionally used to enable a 
sufficiently fat-enriched cream to facilitate ease of de-emulsification during churning 
when producing butter. This natural creaming process is also used in traditional cheese 
making, specifically, for Grana Padana and Parmigiano Reggiano raw milk cheeses as 
a milder bio-process treatment for bacterial reduction and cheese flavour enhancement 
(Fox et al., 2004). In the traditional Parmigiano-Reggiano cheese production process, 
raw milk is stored at 20°C overnight and the milk separates under gravity, following 
which some of the cream layer is removed and fresh raw whole milk is added until a 
final milk of 2.4 to 2.5% fat remains. A similar process is used for Grana Padana, with 
differences observed in milk storage temperature, 15°C, and milk standardised, 2.12.2 
% fat (Fox et al., 2004).  In a study of the effects of time and temperature on changes 
to fat globule size distribution and fat content in milk fractions during gravity 
separation, Ma and Barbano (2000) showed that the volume mean diameter of the top 
layer increased from 3.13 μm (without separation) to 3.48 and 3.64 μm at 4° and 15°C, 
respectively. Euber and Brunner (1984) postulated a theory of fat globule clustering 
involving Immunoglobulin M (IgM) interaction in an antigen-antibody mode 
simultaneously with a fraction extracted by the authors, termed ‘skim milk membrane’, 
and with milk fat globules through specific carbohydrate moieties.  This clustering is 
due to the action of the IgM which is affected by pH, concentration and the valency of 
cations (Kelly and Huppertz, 2006).  Cold agglutination of milk fat globules appears 
to follow similar physiological behaviour to human blood when erythrocytes 
agglutinate and cryo-precipitation to occur when temperature is lowered (Walstra, 
1983).  Cryoglobulin, a protein complex containing IgM, becomes insoluble and 
precipitates on particles in the cold. In milk, the immunoglobulin fraction euglobulin, 
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appears to be largely responsible for the cold agglutination phenomenon (Walstra, 
1983).  More recently, the presence of both somatic cells and immunoglobulins has 
been shown to be necessary for gravity separation of fat, bacteria, and spores in whole 
milk (Geer and Barbano, 2014). The same authors showed that the presence of 
immunoglobulins alone without somatic cells was not sufficient to cause bacteria, fat, 
and spores to rise to the top.  It was speculated that  
IgM functions as a cold agglutinin rather than as a cryoglobulin.   
  
Previous work reported by the authors indicated that a lower incidence of Complement 
activity is evident in fat-reduced and skimmed milks which points towards some form 
of association between Complement and creaming.  Hence, the objective of this study 
was to examine the effect of creaming induced by gravity separation on Complement 
activity of milk sampled simultaneously from different points on a column of milk 
held stationery at 15°C over a 24h period. Additional analyses of each sample included 
characterisation of fat globule size distribution, somatic cell counts and total bacteria 
counts.  
  
  
  
  
  
  
3.3. Materials and Methods  
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3.3.1. Sample preparation -Bovine Milk   
  
Fresh whole bovine milk was aseptically collected from the bulk tank in the Moorepark 
Dairy Production Centre (MDPC) farm using a Milk Sampling Dipper which had been 
sterilised with 70% ethanol.  Experimental work was carried out immediately 
following collection in order to prevent any unmonitored gravitational separation.    
  
3.3.2. Bacterial Strain  
  
Escherichia coli O111 (E. coli NCTC 8007, serotype O111 K58(B4)) a pathogenic  
Complement sensitive strain was purchased from Health Protection Agency Culture  
Collections (Health Protection Agency Culture Collections Porton Down Salisbury 
Wiltshire, SP4 0JG UK).  This strain was routinely grown in Luria-Bertani (LB) 
medium at 37°C with shaking. Standard LB broth and agar was prepared as described  
(Sambrook et al., 2001).    
  
3.3.3. Time-monitored sampling during gravitational separation of cream  
  
The schematic in Fig 3.1 displays a 1000 ml graduated cylinder. Five holes were drilled 
into the graduated cylinder and a small rubber seal was placed into each hole to prevent 
leakage. At sampling times, a sterile needle pierced the seal and 10 ml samples were 
withdrawn into a 10 ml syringe.  The apparatus was maintained at 15°C for 24h and 
milk was withdrawn from each sampling port at 0h, 4h, 8h and 24h.  All the equipment 
was either autoclaved for sterilisation at 121°C for 15 min or wiped with 70% ethanol. 
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The study was conducted in a laminar flow hood in order to minimise the risk of 
environmental contamination.    
  
The adapted graduated cylinder had holes drilled at the 200 ml, 400 ml, 600 ml, 800 
ml and 1000 ml points on the cylinder.  A total of 1100 ml of milk was added to the 
cylinder with an approximate height of 26.5 cm. Fraction 1 was the section with the 
milk above 800 ml, the hole was drilled 4.5 cm from the bottom of the cylinder.  The 
next fractions are 2 (800 - 600 ml) and 3 (600 – 400 ml), the holes were drilled at the 
heights of approximately 4.2 cm and 4.4 cm respectively, while the bottom two 
fractions 4 (400 - 200 ml) and 5 (200 - 0 ml) have heights of 4.8 cm and 4.6 cm, 
respectively.    
  
3.3.4. Fat globule size  
  
The fat globule size (FGS) of the bovine milk was routinely measured using Malvern 
Mastersizer 3000. This equipment uses the laser diffraction principle whereby particles 
passing through a laser beam will scatter light at an angle that is directly proportional 
to their size: large particles scatter at low angles, whereas small particles scatter at high 
angles.  The samples were slowly added drop by drop under moderate stirring at room 
temperature.  Each sample was analysed in triplicate. The size distribution of fat 
globules was characterised by the volume-weighted diameter D[4,3]  
(μm) value as it is regularly referenced in the literature to evaluate size distribution.   
This value, D[4,3], is calculated by the integrated software it may be described simply 
as the mean whenever the result is displayed as a volume distribution.    
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The results were considered as Dv10, Dv50 and Dv90; however, results for Dv90 
provided the clearest insight into particle size, thus, this is reported below. The Dv90 
value signifies that the particle diameter corresponding to 90% cumulative are under 
this fat globule size value.    
  
3.3.5. Milk composition - Fat content  
  
An important marker for this new method is the fat content and so the accuracy of the 
measurement was significant, thus, the fat content was measured by the ISO reference 
method, Rose Gottlieb (ISO, 2010).       
  
3.3.6. Somatic cell count  
  
The SCCs were assessed using a Bentley Somacount 300® (Bentley Instruments Inc.,  
Chaska MN, USA) (ISO, 2006, ISO 2008).    
  
3.3.7 Total bacteria counts  
  
The TBCs were measured using the 3M™ Petrifilm™ Aerobic Count Plates. A serial 
dilution was carried out on each sample and placed on the petrifilm.  The films were 
then incubated at 30°C for 3 days.  The viable cells can be enumerated with a 
specialised Plate Reader which detects a red dye in all viable colonies.    
3.3.7. Bactericidal sequestration assay   
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E. coli O111 was prepared for overnight growth at 37 °C on Luria Betani (LB) agar.  
An isolated colony from replicate plates was inoculated into 3 tubes of LB broth 
(Merck KGaA, Darmstadt, Germany) and grown overnight at 37°C.  The overnight 
cultures were centrifuged at 5000 rpm, a pellet was formed, the supernatant was 
removed and the pellet was re-suspended in phosphate buffer saline solution (PBS 
solution); this step was repeated twice.  On the final step the pellet was suspended in 
LB broth and adjusted to 3 x 108 colony forming units (CFU) per ml using the 
McFarland Method (Goldman et al., 1986).  Using 96-well plates 3 x 20 µl of each of 
the three replicate cultures was added to each round bottomed well (SARSTEDT Ltd., 
Wexford, Ireland) and 80 µl of the sample to be tested was then added.   The plate was 
incubated at 37°C for 2h shaking at 200 rpm (Model Mini 4450 SHKA4450-1CE, 
Fischer Scientific, Ballycoolin, Dublin).  A 20µl sample was taken from each well 
after the incubation time and total viable counts enumerated on LB agar using the pour 
plate method.         
        
3.3.9. Reproducibility and statistical analysis  
  
Throughout the study all work was carried out in triplicate using three separate cultures 
(i.e., three biological repeats) and repeated on three other separate days. Examination 
of the results was done using the SPSS program (SPSS Inc. Released 2009. PASW  
Statistics for Windows, Version 18.0. Chicago: SPSS Inc.).   
  
3.4. Results  
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The laboratory method developed for the purpose of this study exploited the natural 
tendency of fat in fresh un-treated milk to rise to the surface under the influence of 
gravity according to Stokes law - which exploits the density differential between 
globular milk fat and surrounding serum as the driving force behind the physical 
separation of the two phases.  The rapid rate of creaming in milk is due to the rise of 
the smaller individual globules which cluster and, thus, rise to the larger diameter 
spheres.  Conventional centrifugation approaches, on the other hand, accelerate the 
force due to gravity in the course of generating cream.  Hence, by opting for a natural 
process of cream separation over a 24h time period, it was possible to sample from a 
column of milk at 5 ports along its vertical volumetric scale at time intervals of 0h, 4h, 
8h and 24h (Fig 3.1).  In the course of monitoring for gradation in fat concentration 
with increasing height, all milk samples were analysed for fat content, somatic cell 
counts (SCC), fat globule size (FGS), total bacteria counts (TBCs) and bacterial 
sequestration capacity.    
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Figure 3.1 Schematic drawing of gravity separation cylinder closed using rubber seals; 
intermittent holes allowed the fractions 1 – 5 to be removed using a sterile syringe (10 ml) at  
time points over 24h incubation at 15°C.  
3.4.1. Fat globule size  
  
Initially, the mean FGS, expressed as D[4,3], of all 5 fractions were comparable with 
that of raw milk (3.61 μm).  Indeed, fractions 1 (800-1000 ml, 4.5 cm), 2 (600 - 800 
ml, 4.2 cm) and 5 (0 - 200 ml, 4.6 cm) reported an average D[4,3] value of 3.28 μm,  
3.41 μm and 3.36 μm respectively (Fig 3.2).  However, fractions 3 (400 - 600 ml, 4.4 
cm) and 4 (200 - 400 ml, 4.8 cm) had a slightly higher D[4,3] value (3.87 μm and 3.91 
μm, respectively) than that of the raw milk.  Over time, FGS increased to 7.28 μm in 
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fraction 1, in keeping with the expectation that larger milk fat globules rise more 
quickly through the milk.  FGS increases in fraction 2 and fraction 3 initially at the 4h 
sampling time and then declined. This was most likely due to the progression of larger 
fat globules to the upper fraction 1 level during the course of the remaining 20h.  The 
FGS of fraction 4, on the other hand, decreased over time (2.32 μm at 24h) and, 
although it increased initially in fraction 5, at 24h the D[4,3] value decreased to 2.54 
μm.     
  
 
Time (h) 
  Fraction 1  Fraction 2  Fraction 3  Fraction 4  Fraction 5 
  
Figure 3.2 D[4,3] measurements from the Malvern Mastersizer of the fat globule size 
distribution.  A sample was collected from all 5 fractions of the 1000 ml graduated flask at  
set time points over a 24h time period; 0h, 4h, 8h and 24h.    
3.4.2. Dv0.9  
The Dv0.9, representing the 90% of fat globules that fall below the indicated size, 
was initially higher in fractions 3 (6.37 μm), 4 (6.40 μm) and 5 (6.27 μm) (Fig 3.3).  
As fat travels through the milk sample to the top, the largest Dv90 is found in 
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fractions 1, 2 and 3 with values of 7.84 μm, 7.22 μm and 6.64 μm, respectively.  The 
highest Dv90 value occurred in fraction 1 (800 -1000 ml, 4.5 cm) and was closely 
followed by fractions 2 (600 – 800 ml, 4.2 cm) and 3 (400 – 600 ml, 4.4 cm).    
  
 
Figure 3.3 Results of the Malvern Mastersizer measurements for the Dv90 value.   
Samples were collected from each fraction over a 24 time period at 0h, 4h, 8h, and 24h  
  
3.4.3. Fat content  
  
At the start of the study, the fat content of all 5 fractions were similar (4.39%, 4.40%, 
4.41%, 4.24%, and 4.13% fat in fractions 1-5, respectively) to that of raw milk (4.4% 
fat) (Fig 3.4).  According, as cream rose to the top, the fat content of fraction 1 
increased over time to reach a maximum of 14.63% fat after 8h, the fat content of 
fraction 2 increased gradually to an intermediate level of 8.18% over the same time 
period.  As expected, the respective fat content in fractions 3 (400 – 600 ml,4.4 cm),  
4 (200 – 400 ml, 4.8 cm) and 5 (0 – 200 ml, 4.6 cm) declined over time: 3.34% fat,  
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2.17% fat and 1.86% fat at 24h due to the upward mobility of fat globules to the 
creaming zone fractions 1 and 2.  
  
 
Time (h) 
Fraction 1 Fraction 2 Fraction 3 Fraction 4 Fraction 5 
  
Figure 3.4 Results of fat content (%) analysis using the Rose Gottlieb method, each sample 
was collected from the 1000 ml graduated cylinder at set time points over 24h: 0 h, 4h, 8h  
and 24h  
  
3.4.4. Somatic cell count  
  
Throughout the time intervals of this study, the SCC of fraction 1 (800 - 1000 ml at 
4.5 cm) increased with changes in fat content (Fig 3.5). Indeed, the SCCs increased in 
fraction 1 to ~57,000 cells per ml after 24h.  A similar trend was evident with fraction  
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2 (600 – 800 ml, 4.2 cm) where a final SCC count of ~37,000 cells per ml was 
recorded at 24h.  Fractions 3 (400 - 600 ml, 4.4 cm) and 4 (200 – 400 ml, 4.8 cm) SCC 
increased initially to ~31,000 and 37,000 cells per ml, respectively, in the following 
8h fraction  
3 increased to ~28,000 and fraction 4 reduced to ~19,000 cells per ml.  Over the 
next  
16h SCC reduced to ~28,000 and 19,000 cells per ml for fractions 3 and 4 respectively.  
Accordingly, as the fat content reduced in fraction 5, the SCC also declined and 
reached the lowest recorded value by 24h (19,000 cells per ml).    
  
 
  Fraction 1  Fraction 2  Fraction 3  Fraction 4  Fraction 5 
  
Figure 3.5 Somatic cell counts (1000 cells/ml) from the Bentley somacount equipment, each 
sample was collected from fractions 1-5 at set time points over a 24h time frame; 0h, 4h, 8h  
and 24h  
3.4.5. Total bacterial count  
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The TBC in fraction 1 increased over time as bacteria rose to the top of the milk sample 
(Fig 3.6).  The initial TBC of 3.54 log CFU per ml in fraction 1 (800 - 1000 ml at 4.5 
cm) reached a final concentration of 4.06 log CFU per ml after 24h.   TBC also 
increased in fraction 2 (600 - 800 ml, 4.2 cm) from 3.6 log CFU per ml to 3.78 log 
CFU per ml after 8h before dropping off over time to 2.8 log CFU per ml.  Fractions 
3 (400 - 600 ml, 4.4 cm), 4 (200 – 400 ml, 4.8 cm) and 5 (0 - 200 ml, 4.6 cm) shared a 
similar decline of approx. 1 log unit with time to 2.54, 2.36 and 2.17 log CFU per ml.  
  
 
 0 4 8 12 16 20 24 
Time (h) 
  Fraction 1  Fraction 2  Fraction 3  Fraction 4  Fraction 5 
  
Figure 3.6 Total bacteria counts (TBC) in the milk samples collected from the 5 sampling 
ports were completed at each time point (0h, 4h, 8h and 24h).  The values are represented as  
log CFU per ml.    
  
3.4.6. Bactericidal sequestration assay  
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The bactericidal sequestration capacity of fractions 1 (800 – 1000 ml at 4.5 cm) and 2  
(600 - 800 ml, 4.2 cm) increased as reflected in the reduction of viable cells of the 
target microorganism (E. coli O111).  This finding also aligns with the increasing fat 
content in fraction 1 (Fig 3.7).  The viable cell counts reduced from 7.93 log to 7.49 
log CFU per ml in fraction 1 over 24h, while in fraction 2 (600 – 800 ml, 4.2 cm) this 
reduced to 7.64 log CFU per ml.  However, in the milk samples tested from fraction 3 
(400 - 600 ml, 4.4 cm) the numbers of E. coli remained stationary and even increased 
slightly by approximately 0.06 log CFU per ml in the fractions where the fat had been 
somewhat reduced.  The bactericidal capacity of each fraction against E. coli O111 
declined as the fat content reduced in fractions 4 and 5 over time.     
  
 
Time (h) 
  Fraction 1  Fraction 2  Fraction 3  Fraction 4  Fraction 5 
  
Figure 3.7 The bactericidal sequestration assay was also carried out on all samples 
collected.  Results of the bactericidal sequestration assay are expressed in the log CFU per 
ml of the E. coli O111 strain.  The experiment was completed over a 24h period and the  
samples were collected at 0h, 4h, 8h and 24h.   
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3.5. Discussion  
  
The diminished levels of Complement observed in low-fat milks during the early part 
of the study prompted a need to investigate further this phenomenon.  Natural creaming 
of milk according to gravity separation was observed in a 1000 ml graduated flask 
fitted with sampling ports at designated points on the vessel (Fig. 3.1) in order to allow 
milk samples to be extracted  with minimum disturbance of the vessel’s contents.  An 
advantage of this separation method is that any associations taking place 
simultaneously between the globular milk fat and serum phases would not be damaged 
as a result of the increased shear applied by the centrifugal force.  The slow separation 
was effectively achieved after 24 h at 15°C, as the bulk of the fat in the milk had risen 
to the top of the flask.  The temperature of 15°C chosen for this study, was initially 
designed to facilitate a moderate rate of creaming over a 24 h period without major 
levels of bacterial spoilage taking place. This proved later to be fortuitous when it came 
to data interpretation, i.e., it was possible to differentiate from other phenomena taking 
place at the lower temperature of 4°C.   
  
As the milk fat rose in the container, a fat globule size gradient emerged whereby 
larger fat globules occurred in the top layer i.e., FGS fraction 1 (800 -1000 ml, 4.5 cm) 
> Fraction 2 (600 – 800 ml, 4.2 cm) > Fraction 3 (400 – 600 ml, 4.4 cm).  This physical 
phenomenon is underpinned by Stoke’s Law, which predict that larger milk fat  
globules rise faster than their smaller counterparts due to a density differential and the 
velocity effect being proportional to the square of particle diameter (Mulder and 
Walstra, 1974).  However, biochemical phenomena are also implicated, due to 
mechanisms which promote inter alia clustering of smaller fat globules. The 
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phenomenon of agglutination occurring during creaming of milk is attributed to the 
intervention of particular immunoglobulins (Walstra et al., 1983).  Immunoglobulins 
are better known for displaying similar behaviour in blood during the course of 
antigen-antibody reactions. Furthermore, the association of IgM in the aggregation and 
gravity separation of milk is fundamental to the promotion of clustering (Walstra et 
al., 1983).  A temperature-related variation of this, known as cold agglutination, 
involves a similar mechanism whereby a non-specific reaction occurring at ca. 4°C 
results in an insoluble protein complex, comprising of IgM,that induces other particles 
to flocculate (Kelly and Huppertz, 2006).  Described as a cryoglobulin, due to its 
propensity to undergo cold-induced aggregation and precipitation, IgM appears to 
induce temperature-dependent cluster formation, which was indicated by the formation 
of a precipitate from cold whey containing cluster-promoting components  
(Euber and Brunner, 1984).    
  
However, recent research has shown that both SCC and immunoglobulins are required 
for normal gravity separation of milk to occur at 4°C in pasteurised (72°C, 17.31s) 
milk but not following pasteurisation at higher temperature (76°C, 7 min; High 
temperature pasteurisation) (Geer and Barbano, 2014). This confirms that the 
clusterpromoting functionality of immunoglobulins is lost as a result of heat induced 
inactivation during High temperature pasteurisation and no creaming occurs. These 
findings by Geer & Barbano (2014) suggest that the application of Stoke’s Law to 
describe the natural creaming phenomenon in milk is conditional on the biological 
involvement by somatic cells and native immunoglobulins present.  Increased 
Complement-activity in the upper layers observed during the current creaming study 
conducted at 15°C confirms that some form of association between Complement and 
109  
        
globular milk fat exists, and would appear to be independent of the cryo-agglutination 
phenomena that occur at the lower temperature of 4°C.  It should also be noted that 
freshly drawn raw milk samples were used in the current study, in contrast with the 
use of Low or High temperature pasteurisation conditions for the pre-heat treatments 
of milk samples by Geer & Barbano (2014). Such heat treatments would have 
considerably diminished native Complement activity.  As no preheat treatment control 
was employed in the current study, it is not possible to categorically state that the milk 
fat creaming phenomenon observed was due to the activity of immunoglobulins at 
ambient-like conditions (15°C), or purely due to the physical forces of Stoke’s Law at 
play, or even a combination of both. Bacteria and somatic cells did concentrate in the 
upper cream layers, which suggests that agglutination/clustering may be occurring. 
One advantage of conducting this study at 15°C was that it eliminated the simultaneous 
involvement of the cryoagglutination phenomenon (induced at 4°C), so that it is 
possible to conclude that the association of Complement with globular milk fat acted 
independently. Somatic cells were present, albeit at low concentrations, in the current 
study but, as no test control was included, it is not possible to verify whether the SCs 
participated actively or passively in creaming.  
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Chapter IV Transformation of serum susceptible Escherichia coli O111 with 
p16Slux plasmid to allow for real time monitoring of Complement-based inactivation 
of bacterial growth in bovine milk  
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4.1. Abstract   
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Complement activity has only recently been characterised in raw bovine milk.  
However, the activity of this component of the innate immune system was found to 
diminish according as milk was subjected to heat or partitioning during cream 
separation.  Detection of Complement in milk relies on a bactericidal sequestration 
assay.  This assay exploits the specific growth susceptibility of E. coli O111 to the 
presence of Complement. Practical application of the assay was demonstrated when a 
reduction in Complement activity was recorded in the case of pasteurised and reduced 
fat milks.  This presented an opportunity to improve the functionality of the 
bactericidal sequestration assay by incorporating bioluminescence capability into the 
target organism.  Following some adaptation, the strain was transformed by correctly 
integrating the p16Slux plasmid. Growth properties of the transformed strain of E. coli 
O111 were unaffected by the modification.  The efficacy of the strain adaptation was 
verified by correlating (r = 0.966; SEy = 0.957) bioluminescence with that of 
bactericidal sequestration assay total plate counts within the range 7.5 – 9.2 log 
CFU/ml using a combination of raw and processed milk samples significantly, the 
transformed E. coli O111 p16Slux strain could be identified in milk and broth samples 
using bioluminescence measurement, thus enabling the bacterial  assay –viability test 
to be monitored in real time throughout incubation.   
  
  
  
4.2. Introduction  
Bovine milk is substantially adapted during the production of humanised infant milk 
formula (IMF) in order to align its composition with that of human breast milk. 
However, while much progress has been made in addressing nutritional needs of the 
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neonate; little attention has been given to the activity of milk’s defence systems.  
Complement, a part of the innate immune system, is made up of approximately 30 
distinct plasma proteins that interact to opsonize pathogens and induce a series of 
inflammatory responses to help fight infection by killing invading microorganisms 
(Rainard, 2003). Complement is known to be present and anti-pathogenic in human 
breast milk (Ogundele, 2001) and its presence and activity in bovine milk has also 
been reported (Maye et al., 2015, Rainard, 2003, Barrio et al., 2003, Rainard P, 1984).  
Recent efforts to characterise Complement activity in milk have relied on the use of a 
bactericidal sequestration assay which exploits the sensitivity of a specific strain of E. 
coli O111 (E. coli NCTC 8007, serotype O111 K58 (B4) H2) to this innate immune 
protein system (Ogundele, 2002, Monteiro-Neto et al., 1997).  Thus, the growth of 
added E. coli O111 is hindered as a result of the active Complement in milk the extent 
of growth inhibition of the pathogen may be used as an indirect measure of  
Complement activity (Reiter and Brock, 1975a).   Among examples of where this 
bacterial  assay technique has been applied include the measurement and identification 
of Complement activity in mastitic and human milks (Rainard, 1984, Barrio et al., 
2003).    
Previous work by the authors succeeded in detecting residual levels of Complement in 
milks after processing, lower levels being associated with more intense exposure of 
milk to heat, e.g., pasteurisation temperatures, and also in the case of low fat milks.  
Thus, it was felt that there was a need to adapt and improve the bactericidal 
sequestration assay (viability test) by lux tagging of the target microorganism in order 
to elaborate changes taking place to Complement during simulated milk processing  
steps.    
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The authors were recently successful in applying the bactericidal sequestration assay 
to establish Complement activities in freshly drawn bovine milks as seen in Chapter 2.  
Furthermore, it was also discovered that the Complement response was considerably 
reduced during exposure of bovine milks to simulated milk processes such as heating 
and preparation of low-fat milks.  Inactivation of indigenous enzymes in milk such 
alkaline phosphatase is a commonly used bio-marker to prove the efficacy of milk 
pasteurisation. This study was less preoccuppied with the use of Complement as a bio-
marker for calibrating the effectiveness of thermal processes, but more interested in 
the preservation, where possible, of milk’s innate immune properties.  
  
As bovine milk is subjected to considerable processing during manufacture of infant 
milk formula, i.e., pasteurisation, homogenisation, evaporation and spray drying, it 
was felt that an improved bacterial assay would be more useful for real time monitoring 
during operations that give rise to reduced Complement activity.  Lux tagging of the 
target microorganism was deemed to be an appropriate strategy which would allow 
bioluminescent signals to reflect growth and bioluminescence imaging to visualise the 
magnitude of bacterial inhibition speedily during the viability test.  Thus, the initial 
step was to develop a method to introduce the plasmid, p16Slux (Morrissey et al., 2011; 
Riedel et al., 2007a) containing the lux operon derived from Photorhabdus 
luminescens into the E. coli O111 strain. One challenge with this approach was a lack 
of available data on successful genetic modifications to E. coli O111. In addition, 
previous work aimed at rapid detection of this strain identified the existence of a 
number of phenotypes of the O111 organism (Schmidt and Karch, 1996).  However, 
there is some support available in the reporting of successful adaptations of different 
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strains and microorganisms involving the p16 Slux plasmid, e.g., lux-tagging of Gram- 
negative strains such as  Escherichia coli, Salmonella enterica serovar Typhimurium,  
Yersinia enterocolitica, Brucella melitensis, Pseudomonas aeruginosa, and Citrobacter 
rodentium  (Riedel et al., 2007a).   
Thus, the study’s two-fold objective was, firstly, to perform strain transformation to 
ensure consistent expression of the p16Slux in E. coli O111.  Secondly, it was 
necessary to compare and contrast the growth behaviour of the transformed E. coli 
O111 strain alongside that of the original unmodified culture according to the protocol 
of the regular bactericidal sequestration assay.  
  
4.3. Materials and methods  
  
4.3.1. Bacterial strains, media, and chemicals  
  
E. coli O111 (E. coli NCTC 8007, serotype O111 K58 (B4)) a pathogenic Complement 
sensitive strain, was purchased from Health Protection Agency Culture Collections  
(Health Protection Agency Culture Collections Porton Down, Salisbury Wiltshire, SP4 
0JG UK). The strain was routinely grown in Luria-Bertani (LB) medium 37°C with 
shaking.  When required, the antibiotic erythromycin (Sigma Chemical  
Company, St. Louis, MO) was added at a concentration of 500 µg/ml.    
  
4.3.2. Preparation of competent cells and electroporation    
  
Originally, a method described by Dagert and Ehrlich (1979) was undertaken which 
required the withdrawal of 2 ml from a flask containing 200 ml sterile LB broth and 
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its replacement with 2 ml of an overnight culture grown in LB medium.  The inoculated 
medium was grown at 37°C for approx. 2h or until the OD at 600 nm was within the 
range 0.6 – 1.0.  At this point, the 200 ml was equally distributed into 4 sorvall tubes 
and the cells were harvested by centrifugation at room temperature for  
15 min at 15,000 g.  A cell pellet was collected and washed twice with distilled water.  
The cell pellet was then washed using glycerol and finally re-suspended in glycerol 
which contained on average 109 – 1010 viable bacteria.    
  
Unfortunately, this method was unsuccessful and no viable electrocompetent cells 
were established.  A second method was applied which called for 2 ml of the overnight 
cultures to be added to 200 ml of LB broth before growing to an OD at 600 of 0.2 - 0.4 
in approx. 2.5h.  The cells were harvested by centrifugation for 5 min at 5000 g and 
washed twice using CaCl2.  The cells were incubated on ice for 2h between washes.  
The cell pellet was finally collected and re-suspended in glycerol and stored at -80°C 
until required. This method proved to be effective on E. coli O111 and produced 
electrocompetent cells.    
  
The plasmid p16Slux, kindly donated by Professor Colin Hill’s research group in 
University College Cork, Ireland, was prepared using the Qiagen mini-prep kit as 
previously described, and integrated into the E. coli O111 bacterial chromosome by 
homologous recombination (Riedel et al., 2007b).  For electroporation, 7 µl of the 
p16Slux was purified using the Qiagen plasmid mini-prep kit and was mixed with 50 
µl of the electrocompetent E. coli O111. This mixture was transferred to a 5 mm gap 
width electroporation cuvette and placed in a BTX Electroporation System (Harvard  
Apparatus, Holliston, USA).      
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4.3.3. Sample preparation  
  
Fresh whole milk was collected from the Moorepark Dairy Production Centre  
(MDPC) farm on the day of testing.  An Armfield disc bowl centrifuge (Armfield, 
Ringwood, UK) was used in the laboratory to generate cream samples (approximately  
40% fat) and skimmed milk (approximately 1% fat) from the fresh raw milk. 
Commercially pasteurised bovine milk was purchased from local supermarkets on the 
day of testing.    
All samples were analysed for TBC using the reference ISO methods ((ISO 2004, ISO  
2013).  The SCC of the raw, skimmed and retailed milks was determined using a  
Bentley Somacount 300® (Bentley Instrument Inc., Chaska MN, USA). Milks with 
SCC < 200,000 cells per ml were selected for bacterial assay in order to avoid false 
positive results being contributed by the high levels of other immune factors like 
immunoglobulins and leukocytes triggered in the wake of mammary infection.    
  
4.3.4. Control preparation  
Freshly collected raw milk was heat treated at 56°C for 30 min to ensure complete 
inactivation of the complement protein (Korhonen et al., 2000).  All samples were 
screened using the ISO methods (ISO 2004, ISO 2013) and also the milks were 
streaked on Nutrient and Luria Bertani agar.    
  
4.3.5. Bactericidal sequestration assay – viability test  
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Wild type E. coli O111 and the transformed E. coli O111 was prepared for overnight 
growth at 37°C on Luria-Bertani (LB) agar as described (Sambrook et al., 2001).   
Isolated colonies was picked from replicate plates and inoculated into three tubes of  
LB broth (Merck KGaA, Darmstadt, Germany) and grown overnight at 37°C at 200 
rpm.  After approx. 18 – 24h, the overnight cultures were centrifuged at 5000 rpm, 
followed by re-suspension of the resulting pellet in phosphate buffer saline solution 
(PBS solution) - this step was replicated twice.  Following this, the pellet was 
resuspended in LB broth and adjusted to 3 x 108 colony forming unit per ml (CFU per 
ml) using the McFarland method.  Using 96-well plates, 3 x 20 μl of both strains were 
added to each round-bottomed well (Sarstedt Ltd. Wexford, Ireland) and 80μl of the 
sample to be tested was then added.  The plate was placed in a shaking incubator 
(Model Mini 4450 SHKA4450-1CE, Fischer Scientific, Ballycoolin, Dublin) at 200 
rpm for 2h at 37°C.  A 20 µl sample was taken from each well after incubation; total 
viable counts were enumerated on LB agar.         
  
  
  
4.3.6. Monitoring of growth in LB broth by performing viable plate counts and 
measuring bioluminescence  
  
Overnight cultures of both the wild type (WT) and transformed E. coli strain were 
grown in LB broth.  Erythromycin was included in the LB broth in order to support 
the transformed strain from reverting to its original form.  These were centrifuged at 
room temperature for 15 min at a speed of 5000 g, followed by washing with PBS and 
re-suspension in LB broth.  Twenty µl of inoculum was then added to fresh LB broth 
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and grown in a shaking incubator at a speed of 200 rpm and temperature of 37°C.  
Samples were collected at 1h intervals and viable plate counts were carried out to by 
plating dilutions onto LB agar.  Two hundred microliters of the freshly inoculated LB 
broth was added to a 96 - well white plate (Nunc, Thermo Fisher Scientific, Roskilde, 
Denmark), and optical density was measured hourly using a Synergy HT plate reader 
(Bio-Tek Instruments, Inc., Winooski, VT). Simultaneously, bioluminescence was 
also measured in photons per second per square centimetre with an IVIS Xenogen 
Imaging 100 system (Xenogen, Alameda, CA) with a binning of 16 and an exposure 
time of 1 min.    
  
4.3.7. Evaluation of minimum inhibitory concentration of the WT and transformed E. 
coli O111 in erythromycin  
  
Both strains of E. coli O111 were tested according to the M.I.C.E strips (Ovoid Ltd, 
Basingstoke’s Hants, RG24 8PW, England) method which gives an accurate minimum 
inhibitory concentration (MIC) over the range 256 – 0.015 μg/ml. This was to confirm 
that tolerance to erythromycin of p16Slux plasmid was conferred on E. coli O111 
following transformation. (Riedel et al., 2007a)   
  
4.3.8. Molecular biology experiments   
  
PCR reactions were performed on the wild type E. coli O111 and transformed E. coli  
O111 using Biomix red (Mybio, Kilkenny, Ireland), primers were purchased from  
Eurofins (MWG, Ebersberg, Germany)     
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16S fwd (5’-ACACTGGAACTGAGACACGGTCCAGACTCC-3’) and  
16S rev (5’-TTGTAAAACGACGGCCAGTGAGCGCGCG-3’)  
to verify that the p16Slux plasmid had correctly integrated at the preferred location.   
The PCR reactions were carried out using a T3000 Thermocycler (Biometra, 
Gottingen, Germany) as previously described (Morrissey et al., 2011) with the addition 
of a preliminary “hotstart” step. Gel electrophoresis was performed using the Power 
pack 200 (Bio-Rad, Hercules, CA, United States of America) - 4 μl of the PCR 
products were routinely run on 1% agarose gels (Invitrogen, Carlsbad, CA) at 90 V 
and 2 A for 60 min.    
  
4.4.Results    
  
4.4.1. Transformation of the E. coli O111 strain   
  
Following the utilisation of two separate methods to successfully transform E. coli  
O111, the mutation was ultimately effective.  Finally, the p16Slux plasmid became 
well established within E. coli O111 following electroporation (Riedel et al., 2007a).  
The exact location of plasmid integration was confirmed by means of PCR using 
primers specifically designed to address the target integration site. Gel electrophoresis 
carried out on PCR products e.g. the identification of a 1,163-bp band produced 
confirmed the correct positioning of the plasmid (Fig 4.1).    
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Figure 4.1 Electrophoresis gel showing the approx. 1,163bp band which confirms the 
presence of the p16 Slux plasmid which integrates into the 16S rRNA gene of Gram-  
negative bacteria. Lane 1 is the p16 transformed strain, lane 2 is the wild type strain; as 
expected, there is a band present in lane 1 indicating the successful integration of the plasmid 
in the correct position in the transformed E. coli O111 strain. Furthermore, PCR and gel 
electrophoresis performed on the unmodified E. coli O111 strain revealed that no PCR 
product was amplified from this strain.    
  
4.4.2. Observation of growth properties of both strains  
  
The WT and genetically modified strains of E. coli O111 were grown overnight on LB 
agar, it was found that both forms of E. coli  were similar in terms of size, shape  
(round) and colour (cream).   
  
Ladder  
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  O111  O111p16 
  
Figure 4.2  Total viable count of WT E. coli O111 compared to the transformed p16Slux E. 
coli O111 in LB broth.  The measurements are represented as log CFU per ml.  Both strains 
were grown over night in a shaking incubator at 37°C and 200 rpm for 27h in LB broth.  
Importantly, there was no significant difference (p < 0.05) identified through 
enumeration of total viable counts during overnight growth of the isolated colonies in 
LB broth at 37°C, with values of 8.13 and 8.01 log CFU per ml for the WT and 
transformed cultures respectively (Fig 4.2); moreover, hourly measurement of 
absorbance readings at 600 nm identified similar growth as seen in Fig 4.3.    
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Figure 4.3  Absorbance readings (600 nm) of E. coli O111in LB broth, genetically modified  
E. coli O111 in LB broth, wild type E. coli O111 in LB broth with 500 μg/ml erythromycin, 
(X) genetically modified E. coli O111 in LB broth with 500 μg/ml erythromycin,  (log10  
CFU/ml) during incubation at 37°C for 21h.  
Furthermore, the luminescence remained relatively stable throughout the entire growth 
curve, as was seen in previous studies (Riedel et al., 2007a); this was confirmed by the 
correlation between the reduction in luminescence ROI and respective CFU counts.  
Overall, it can be concluded that the growth properties of E. coli O111 strain remained 
intact after genetic modification involving plasmid insertion.    
  
4.4.3. Confirmation of effects of the p16Slux plasmid.   
  
Confirmation of acquired antibiotic resistance in the newly transformed strain to 
erythromycin was demonstrated during 21h incubation at 37°C in LB broth in the 
presence of erythromycin (Fig 4.3), while the WT E. coli O111 was unable to grow 
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under these conditions. In addition, the transformed strain produced strong 
bioluminescent readings in the images (Fig 4.4a and 4.4b) captured from the Xenogen  
IVIS, while the WT strain did not release any bioluminescence.   
 a.            b.  
  
Figure 4.4a. Bioluminescence image of transformed E. coli O111 alongside the original 
unmodified wild type strain of E. coli O111 and Figure 4.4b representing the higher levels of 
transformed E. coli O111, the image was captured on a Xenogen IVIS 100 imager, culture  
was grown overnight on LB agar at 37°C.  
Confirmation of tolerance to erythromycin of the transformed E. coli O111 strain is 
evident according to the lack of inhibition in the immediate zones of the M.I.C.E strips  
(Fig 4.5), thus, concurring with the functionality cited for the plasmid insert by Riedel, 
Casey et al., (2007).  By contrast, a considerable area of clearance may be seen in the 
case of the WT strain.  
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Figure 4.5  (a) Lack of inhibition in the immediate zones of the M.I.C.E strips provides 
confirmation of tolerance to erythromycin of the transformed E. coli O111 strain. (b) A 
considerable area of clearance may be seen in the case of the WT strain.  
  
4.4.4. Application of transformed E. coli O111 p16Slux plasmid  
  
Bioluminescent imaging was monitored in real time during the performance of the 
bactericidal sequestration assay involving the transformed E. coli O111 strain.  The 
efficacy of strain adaptation was illustrated by the bioluminescent images captured, 
initially and after 2h (Fig 4.6) shaking incubation (37°C at 200 rpm) of p16Slux E. coli 
O111 in heat-treated (56°C, 30 min) milk, freshly-collected raw milk, skim milk and 
commercially retailed full-fat milk.     
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Figure 4.6  Growth of transformed Escherichia coli O111 at initial inoculation and 
following 2h incubation in (i) laboratory prepared skim milk, (ii) raw bovine milk, (iii) 
commercial pasteurized milk, and (iv) heated bovine milk (control) during the bactericidal 
assay for 2h at 37°C. Bacteria were counted in the red circled regions of interest (ROI).  
The luminescent data overlaid on the photographic image of the clear 12-well plate  
(Fig 4.6) utilises a pseudocolor scheme which aids in the observation of light emission.  
In the brighter area of the image, more photons are detected and the photon intensity 
number is greater than in the less bright areas.   
This is best described by tracking colour change from the time of initial inoculation to 
termination after 2h incubation of p16Slux E. coli O111 in a variety of treated milk 
substrates.  Exponential growth of the culture in retailed pasteurised milk and heated 
bovine milk was represented by bright red and yellow light emission.  However, the 
lighter blue coloured zones were a consequence of lower light emission when the 
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growth of transformed E. coli O111 was inhibited in skim milk, and most notably, in 
the raw bovine milk (due to Complement activity).    
The corresponding results generated by the bactericidal sequestration assay using the 
genetically modified E. coli O111 p16 Slux strain for the control heat treated milk 
(56°C, 30 min), raw bovine milk, commercial retailed milk and lab-prepared skim milk 
were 9.18, 8.60, 7.70 and 8.58 log CFU/ml, respectively (Fig 4.7).  This data coincided 
with the region of interest (ROI) photon measurements undertaken concurrently, in 
which the differences in bioluminescence intensity reflected changes in the 
aforementioned bacterial growth.  The reduced total viable counts of E. coli O111 in 
raw bovine milk lower (p < 0.05) compared to skim, retail pasteurised and heat-treated 
control bovine milks reflected its stronger bacteriostatic effect due to Complement 
(Reiter et al., 1975a; Reiter and Brock, 1975b).    
 
Figure 4.7 Growth of the transformed Escherichia coli O111 p16Slux (log10 CFU/ml) during 
bacterial sequestration assay at after 2h incubation with (i) heated bovine milk  
(control), (ii) commercial pasteurized milk, (iii) raw bovine milk, and (iv) laboratory 
prepared skim bovine milk. Error bars indicate standard deviation of triplicate assessments.  
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Hence, incorporation of bioluminescent imaging via genetic modification to enhance 
the functionality of the probe microorganism is an effective enhancement of the assay 
for monitoring Complement activity in various unprocessed and processed milks.  
According to the independent-samples t-test, there was a significant difference (p < 
0.05) between all samples tested and the raw bovine milk, while statistically there was 
no significant difference (p < 0.05) between the lab-prepared skim milk and retail 
pasteurised samples.   
  
4.4.5. Relationship between bacterial counts and bioluminescence of E. coli O111  
  
The correlation between the traditional TBC and the adapted bioluminescent 
measurements the data was analysed (Fig 4.8).  It can be seen that the adapted 
bioluminescent based sequestration method is strongly correlated to the unmodified 
assay according to the equation y = 0.9748x + 0.2133 with a correlation coefficient 
(R) 0.966, and a coefficient of determination (R2) of 0.933.  The standard error of 
prediction value is 0.957.        
These studies confirm that the objective of inserting a p16 Slux plasmid into E. coli 
O111 in order to generate a bioluminescent response during subsequent growth was 
successfully accomplished.  This transformed strain, which was originally used as an 
analytical probe in the bio-sequestration assay to detect the presence of Complement 
activity in human milk (Ogundele, 2002), and more recently in bovine milk (Maye et 
al., 2015) may now be utilized to measure antimicrobial response in real time 
throughout the bactericidal sequestration assay.  This adds greater certainty to the test 
given the diversity of other innate bacterial strains present in non-pasteurised milk, in 
particular, strains which may lead to the risk of false positive identifications. 
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Furthermore, erythromycin resistance conferred on the transformed E. coli O111 also 
allows the strain to be selectively screened for by means of susceptibility tests with 
antibiotic-containing agars.  
  
Finally, application of the now upgraded bactericidal sequestration assay confirmed 
the earlier findings of Maye et al. (2015) that pasteurisation (retail pasteurised milk) 
and cream removal (lab-separated skim milk) contributed to substantial loss of 
Complement activity but, importantly, some residual Complement activity is 
detectable in both the lab- prepared skim milk and pasteurised milk.  
  
 
  T2  Linear (T2) 
   
Figure 4.8 Assessment of the relationship between the bacterial counts of E. coli O111  
measured by luminescence and total plate counts.    
4.5.Discussion  
  
y = 0.9748x + 0.2133 
R² = 0.933 
5.00 
6.00 
7.00 
8.00 
9.00 
10.00 
5.00 6.00 7.00 8.00 9.00 
log no. photons of bacterial cells 
132  
        
The transformation of E. coli O111 proved to be challenging due to the relatively 
unknown response of E. coli O111 to genetic transformation and shortage of data in 
existence for the relevant strain.  Moreover, a relevant study to rapidly identify E. coli 
O111 in food recognised much variance in phenotype within the O111 group, which 
suggested possible difficulty during attempts to modify the strain (Schmidt and Karch, 
1996).  For this reason, the initial method to prepare an electrocompetent strain was 
unsuccessful, while the second method, which featured additional adaptations such as 
the use of calcium chloride and altered temperature regimes, was ultimately effective.  
The insertion of the p16Slux plasmid transforms the strain and allows it to tolerate the 
antibiotic erythromycin; moreover, it affords the ability to emit bioluminescent light 
and in this way the strain can be measured quickly and allows real time monitoring.  
Finally, the p16Slux plasmid became well established within E. coli O111 following 
electroporation to the electrocompetent cells  (Riedel et al., 2007a).  The exact location 
of plasmid integration was confirmed by means of PCR using primers specifically 
designed to address the target integration site.  It was confirmed that this modification 
did not affect the strains growth properties or appearance, further, serum susceptibility 
was maintained in the strain.  Moreover, we also found that the luminescence was 
relatively stable throughout growth phases.      
The next step was to include the transformed strain in the bactericidal sequestration 
assay.  By considering the changes in the pseudocolour scheme, it could be seen that 
there was exponential growth of the culture in retailed pasteurised milk as well as in 
the heated bovine milk.  In the skim and raw bovine milk there was restricted growth 
of the transformed strain.  This was most significant in the raw bovine milk, which 
was further confirmed by the bactericidal sequestration assay whereby the raw milk 
was the most potent for restriction of transformed E. coli O111.     
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Hence, incorporation of bioluminescent imaging via genetic modification to enhance 
the functionality of the probe microorganism is an effective enhancement of the assay 
for monitoring Complement activity in various unprocessed and processed milks.    
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Recently published work as described in Chapter 2 highlighted the extent of 
Complement activity in bovine milk.  Localised mastitic infection occurring in the 
mammary glands of dairy cows is readily detectable by the levels of somatic cells in 
milk.  Thus, it is opportune to monitor Complement activity in milks in association 
with the animal’s innate immune response to mammary infection.   
  
Preliminary screening of milk samples taken randomly showed that milk with a high 
somatic cell count (SCC) reduced growth of the Complement-sensitive strain E. coli 
O111 to a greater extent (p < 0.05) than when the marker microorganism was grown 
in milk heated for the purpose of inactivating Complement.  A follow-up study set out 
to determine the effect on Complement activity when a sub-clinical mastitic infection 
was induced in the mammary gland of four lactating dairy cows.  The effect of Str.  
dysgalactiae spp. dysgalactiae inoculation into selected individual udder quarters of 
the mammary glands of each animal was followed by monitoring of SCC levels in the 
milks from the segregated udder samples during subsequent milking. At 72 and 96h 
post inoculation (PI), the SCCs for the challenged quarter increased to 6.73, 6.76, 6.84 
and 6.71 log SCC per ml compared to normal values (approx. 4.38 log SCC per ml). 
At the same time, the bactericidal sequestration assay identified increased E. coli 
O111 inhibition that can be directly linked to greater Complement activity in those 
quarter milks affected by induced inflammation. The high SCC milks identified that 
all cows were more effective in limiting E. coli O111 growth PI, i.e., log CFU per ml 
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of E. coli O111 for all four cows numbered at day 2 was between 6.69 and 7.92, in 
contrast to the control quarters which had values ranging from 8.27 to 8.45 log CFU 
per ml. Milks from the unchallenged quarters in all four cows were significantly less 
effective at reducing growth of the assay strain (p < 0.05).    
  
An ELISA assay targeting specific activation components of the Complement 
pathways confirmed that greater bacterial inhibition observed during the bactericidal 
sequestration assay was attributable to due to higher Complement activity in the milk 
samples from the affected quarters, i.e., with higher SCC.  The induced infection was 
confirmed as self-limiting in three of the affected animals and their SCC returned to 
normal levels within 14 d PI, while the fourth cow required brief antibiotic 
intervention.   
  
5.2. Introduction  
  
There is considerable evidence to support the importance of passive immunity, 
present in breastmilk, in protecting of the neonate during the early stages of life 
(Goldman et al., 1986, Butler, 1979).  As it requires some time for new-born babies 
immune system to be fully developed, mother’s milk plays a crucial role in delivering 
protection and development.  These innate immune components elicit a potent 
response against a large array of invading microorganisms.  Important factors include; 
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antibodies, TNFα receptors, interleukin (IL)-1RA, partially digested lactoferrin, anti-
inflammatory cytokines IL-10 and transforming growth factor. In addition, human 
breast milk also contains some antioxidants, protease inhibitors and prostaglandins.  
Beneficial lactobacilli and bioactive bifidus factors have also been isolated and 
measured in higher quantities in breast-fed infants compared to their formula-fed 
counterparts.  Thus, the absence or limited presence of these beneficial  factors in 
infant formula is likely to lead to a higher incidence of health disorders of an enteric 
nature, including inflammatory bowel diseases (Newburg, 2007, Tasnim, 2014).    
  
Complement is a major component of the innate immune response and is known to 
provide protection in human breast milk against invading microorganisms (Ogundele, 
2001).  Its role is believed to be bactericidal, a biological marker that is defined by 
the bactericidal sequestration assay used to determine its presence (Ogundele, 2002).  
Originating in the blood and tissues of the lactating mammal, precursor zymogens of 
the Complement system at the sites of infection are activated locally and trigger a 
series of potent inflammatory events.  It is known that a number of the Complement 
proteins are classified as zymogens which are proteases activated by proteolytic 
cleavage.  These zymogens act at specific sites of infection to trigger a series of potent 
inflammatory events and also contribute to the activation of some components of the 
Complement system (Janeway et al., 2001).  Following initiation, a cascading 
mechanism made up of 30 serum and non-serum proteins stimulate auxiliary 
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components of the innate immune as well as working alongside and promoting the 
adaptive immune system.  Complement activity has recently been detected in freshly 
drawn  bovine milk with an approx. eighty per cent bactericidal efficacy compared to 
human milk against the assay target bacterium (E. coli O111) (Maye et al., 2015).  
This finding raised questions as to the origin of Complement in milk, particularly with 
respect to mammalian immunity and transmissibility of innate immune components 
to milk.  The inflammatory response is a process in the body which activates the 
required components to eliminate invading organisms and also to initiate tissue repair.  
Some of these antibacterial activities include increased levels of lactoferrin and 
specific blood proteins such as immunoglobulins and complement components 
(Pyörälä and Mattila, 1987).  
Mastitis is as an inflammation of the mammary gland that affects lactating 
mammalian species  (Sordillo and Streicher, 2002) and is ranked highest (16.5% in 
2007) in terms of morbidity (±0.5 SD mean) expressed as a percentage of all cows in 
the USA (Sordillo, 2009).   
Mastitis is categorised as either clinical or subclinical according to the degree of 
severity.  The subclinical form in most cases may only detected using laboratory 
techniques and is widely undetected at farm level.  However, clinical cases of 
infection are accompanied by fever, swelling of the udders as well as milk exhibiting 
a watery appearance, flakes, clots, or pus.  In more serious cases (mostly associated 
with Escherichia coli), it is accompanied by clinical signs such as a reduction in milk 
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yield, elevated body temperature, lack of appetite, sunken eyes and signs of diarrhoea 
and dehydration.  A major cause of mastitis is known to be due to microorganisms, 
the most pertinent causative agents being of bacterial origin.  Staphylococcus aureus, 
Streptococcus agalactiae, Str. dysgalactiae, Str. uberis and Escherichia coli are the 
common causes of bovine mastitis.  Other strains have also contributed to occasional 
herd outbreaks of mastitis.  In general, mastitis occurs following entry by pathogens 
into the teat canal of cows.    
From a consumer perspective, it is valuable to know that innate immune components 
contribute to the overall biological value and anti-pathogenic effects of milk.  At the 
same time, there is little knowledge of how such innate immune factors are affected 
by the health status of the lactating cow. Hence, it was opportune to explore mastitic 
infection as a health disorder with which to monitor changes in Complement activity 
in milks drawn from both healthy as well as udder quarters showing the first clinical 
signs of mastitis in the secreted milk, i.e., containing high SCC.  
Given the association of Complement with the innate immune system, it was 
hypothesised as to how well the passive immune response could be activated in a 
controlled manner by inoculating Streptococcus dysgalactiae spp. dysgalactiae into 
individual udder quarters of mammary glands.  In the immediate aftermath, it was 
necessary to quantify the level of active Complement partitioning into milk from 
infected and non-infected mammary quarters of treated cows. It was also opportune 
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to make a general assessment of the extent of the relationship between elevated SCCs 
and the bacteriostatic potential of milks produced during the trials.    
  
5.3.Materials and Methods  
  
The experimental procedures carried out in the following sections were performed 
under licence from the Irish Department of Agriculture and Food, Agriculture House,  
Kildare St. Dublin 2, Ireland.   
  
5.3.1. Milk samples  
  
Fresh whole milk was collected from the Moorepark Dairy Production Centre  
(MDPC) farm on the day of testing.  For part one of this studu milk was collected 
from 3 individual animals on 3 consecutive days at the morning milking time.  Each 
milk sample was screened for presence of pathogenic microbes and levels of bacteria 
present were measured using ISO 16917/IDF 161 method (ISO 2013).  The SCC was 
also assessed using ISO methods using Bentley Somacount 300® (Bentley 
Instruments Inc., Chaska MN, USA).  Milks were classified according to high SCC, 
i.e., >200,000 cells per ml, while low SCC milks were <100,000 cells per ml.  For 
this part cows were selected with quarters exhibiting both high and low SCCs for the 
preliminary study. Milk was collected from the individual quarters of each cow 
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containing high and low SCC and assessed using the bactericidal sequestration assay.   
For the subsequent inoculation trials, milk samples were aseptically collected from 
individual quarters from cows who maintained the selection criteria outlined below.  
SCCs were monitored 7 days pre- and up to 12 days post inoculation (PI).  Bulk milk 
samples were closely monitored up to 2 months following inoculation.    
  
5.3.2. Control preparation  
  
Freshly collected raw milk was heat-treated at 56°C for 30 min to ensure complete 
inactivation of the complement protein (Korhonen et al., 2000).  All samples were 
screened using the ISO methods (ISO 2013, ISO 2004) and also the milks were 
streaked on Nutrient and Luria Bertani agar.    
  
5.3.3. Animal selection  
  
The animals selected were from the dairy production centre in Moorepark Fermoy, 
Co. Cork and were chosen based on their low SCC as well as long term and up-to-
date infection information.  Seven days pre intra-mammary challenge, all animals and 
individual quarters were inspected by trained staff; to be selected, each animal 
required a healthy appearance.  SCC was monitored from all cow milk samples to 
ensure no increase in levels due to infection.  The milks were also screened using 
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violet red and aesculin blood agar to monitor background bacteria (results not shown).  
Violet red agar is used to detect the levels of coliforms in food or dairy products.  
Blood aesculin agar selects for the growth of Staphylococci, Streptococci as well as 
S.uberis by means of the aesculin cleaving.  The growth of coliform bacteria, 
pseudomonads and yeasts is also possible on non-selective agar.  For the purpose of 
this study these agars were used to monitor any significant changes in the milk other 
than the Streptococcus dysgalactiae.   
  
5.3.4. Bacterial strains   
  
A strain of Str. dysgalactiae spp. dysgalactiae previously isolated and identified from 
an animal in the Dairy Production centre in Teagasc Food Research Centre, 
Moorepark, was used for the intra-mammary challenge.    
Escherichia coli O111 (E. coli NCTC 8007, serotype O111 K58(B4)) a pathogenic  
Complement sensitive strain was purchased from Health Protection Agency Culture 
Collections (Health Protection Agency Culture Collections Porton Down Salisbury 
Wiltshire, SP4 0JG UK).  This strain was routinely grown in Luria-Bertani (LB) 
medium at 37°C with shaking. Standard LB broth and agar was prepared as described 
by Sambrook et al., (2001).    
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5.3.5. Intra-mammary challenge   
  
S. dysgalactiae spp. dysgalactiae DPC 5435 described was grown at 37°C in tryptic 
soy broth (Difco Laboratories, Detroit, USA). Following this the overnight cultures 
were serially diluted and plated to determine CFU count. 200 μl of this culture was 
diluted with 1.8 ml of maximum recovery diluent (MRD, Oxoid) and this 2 ml 
suspension (containing 2500 CFU S. dysgalactiae spp. dysgalactiae) was used for the 
challenge.  Infusions as well as milk sampling were performed under licence from the  
Irish Department of Agriculture and Food, and the cows’ health was subsequently 
monitored by trained farm staff and veterinary personnel. For animal welfare 
purposes, where clinical signs of infection were observed, intra-mammary challenged 
cows received antibiotic treatment.  
  
5.3.6. Bactericidal sequestration assay   
  
E. coli O111 was prepared for overnight growth at 37°C on LB agar.  An isolated 
colony from replicate plates was inoculated into 3 tubes of LB broth (Merck KGaA, 
Darmstadt, Germany) and grown over night at 37°C.  The overnight cultures were 
centrifuged at 5000 rpm, a pellet was formed, the supernatant was removed and the 
pellet was re-suspended in phosphate buffer saline solution (PBS solution) this step 
was repeated twice.  On the final step, the pellet was suspended in LB broth and 
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adjusted to 3 x 108 colony forming units (CFU) per ml using the McFarland Method 
(Goldman et al., 1986).  Using 96-well plates 3 x 20 µl of each of the three replicate 
cultures was added to each round bottomed well (SARSTEDT Ltd. Wexford, Ireland) 
and 80 µl of the sample to be tested was then added.   The plate was incubated at 37°C 
for 2h shaking at 200 rpm (Model Mini 4450 SHKA4450-1CE, Fischer Scientific, 
Ballycoolin, Dublin).  A 20 µl sample was taken from each well after the incubation 
time and total viable counts enumerated on LB agar using the pour plate method.    
  
5.3.7. C5a ELISA assay    
  
A C5a ELISA kit (BlueGene, Shanghai, China) assay was purchased and used in 
parallel to the Bactericidal sequestration assay.  The fresh milk samples were run in 
the ELISA assay on the day of collection.  This assay was used to detect the levels of 
convergent C5a Complement protein in the milks.    
  
5.3.8. Reproducibility and statistical analysis  
  
Throughout the study all work was carried out in triplicate using three separate 
cultures (i.e., three biological repeats) and repeated on three other separate days. 
Examination of the results received was done using the SPSS program (SPSS Inc. 
Released 2009.  
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PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc.)  
5.4.Results  
  
5.4.1. Complement activity in milks with high and low somatic cell counts  
  
Preliminary screening was carried out to investigate the extent of the association 
between SCC and Complement activity.  Three cows with elevated SCCs (> 200,000 
cells per ml) in individual quarters were selected from the MDPC dairy herd.  Milk 
was aseptically collected from the individual high and low SCC quarters of each cow 
and tested by the bacterial sequestration assay.  Milks from those quarters of 
individual animals with high SCC inhibited most (p < 0.05) of the growth of the 
Complementsensitive strain, E. coli O111, compared to the control (heat-inactivated 
milk).  However, when the high SCC milks from affected quarters of Cows 1, 2, and 
3 were compared to milks from their healthy quarter (low SCC < 100,000), the 
difference was not significant (p>0.05), based on respective E. coli O111 growth 
values of 8.08, 7.60 and 8.12 log CFU/ml for high SCC and 8.21, 7.97 and 8.34 log 
CFU/ml (low SCC milks).  In any case, it needs to be remembered that low SCC raw 
bovine milk also contain active Complement with bacteriostatic capabilities as it has 
not been heat treated (Maye et al., 2015).    
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Figure 5.1 Results of the bacterial sequestration assay of the milk samples from individual 
cows in the MDPC herd.  Each cow had a quarter producing both high and low SCC milks.  
The samples include; (i) heat treated raw bovine milk (control, 56oC 30 min), (ii) Cow 1 qtr 
with high SCC, (iii) Cow 1 qtr with low SCC, (iv) Cow 2 qtr with high SCC, (v) Cow 2 qtr 
with low SCC, (vi) Cow 3 qtr with high SCC, (vii) Cow 3 qtr with low SCC.    
Overall, the results of this pre-screening experiment indicated that innate immune 
components were evident in the high SCC milks according to the higher 
Complementbased bactericidal activity.  As this was a preliminary study, it was not 
possible to identify the stage of inflammation in the case of high SCC milks, e.g., the 
cow may be at either the initiation stage or in the phase of recovery following 
infection. It was also evident that the innate immune response to infection in one 
quarter was not manifested in the adjoining healthier quarters, and so it may be 
7 
7.2 
7.4 
7.6 
7.8 
8 
8.2 
8.4 
8.6 
8.8 
150  
        
  
  
concluded that Complement activation would appear to be localised at the site of 
infection.    
Additionally, it can be seen that high and normal SCC milks had significantly reduced  
E. coli O111 growth rates in comparison to the control (p < 0.05), i.e., a milk in which 
Complement has been heat-inactivated (56oC for 30 min) as described by Korhonen  
et al., 2000a.    
  
5.4.2. Intra-mammary challenge of individual quarters with Streptococcus  
dysgalactiae   
  
In a follow-up study, the bovine immune system response was deliberately challenged 
by inoculating an infectious strain Str. dysgalactiae into one (healthy) quarter of 4 
selected cows from the MDPC herd.  Subsequently, milk was aseptically collected 
periodically at designated milking intervals (7h, 12h, 24h, 48h, 72h and 7d, 14d and 
21d PI) from both an unchallenged control quarter and an infused quarter.  During 
follow-up sampling and screening, viable Str. dysgalactiae were recovered at 7h and 
24h from the infused quarters of all four treated cows.  Importantly, there were no 
other pathogenic strains isolated from the milk drawn from the affected quarters 
throughout the trial.  Equally, all of the uninfected control quarters remained free of 
pathogenic microorganisms throughout this period also.   
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5.4.3. Clinical response and milk characteristics   
  
Following infusion, all 4 cows presented with signs of udder inflammation in the test 
quarters 24h PI. The cows were monitored individually for the anticipated signs of 
mastitis, e.g., inflammation and swelling of challenged quarters, increased levels of 
SCC and expressed milk with abnormal signs such a watery appearance, flakes, clots 
or pus. It was observed that the SCC of the tested quarters for all 4 animals peaked at 
times between 72 and 96h PI.  At this time, clots were visible in the milk collected 
from the infused quarters, and the SCCs for the challenged quarter increased to 6.73,  
6.76, 6.84 and 6.71 log SCC per ml for cows numbered 1 to 4, respectively (Fig 5.2). 
Hence, it was concluded that the Str. dysgalactiae infection was now established, so 
that the immune response in the inoculated quarters could be monitored. The control  
(uninfected, healthy) quarters did not show any significant change in SCC (p < 0.05). 
Close monitoring of udder conditions and milking from the four cows continued 
during the period following establishment of peak infection. The infection was 
selflimiting in the case of three of affected animals, and their SCCs returned to normal 
levels within 14d PI, while the fourth cow required brief antibiotic intervention. SCC 
surveillance continued for up to 30d PI in order to ensure that all cows returned to and 
maintained a healthy lactating status.  
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 time (d) time (d) 
      
Figure 5.2 The individual SCCs (log cells per ml) for both the challenged quarter and the control.  The SCC was measured from 7 d prior to intra-mammary  
challenge until d 18 PI  
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5.4.4. Viable bacteria enumerated from collected milk pre and post -inoculation   
  
Milks were first screened using ISO reference methods (ISO, 2004) for bacterial 
growth in order to identify the rate of growth and survival of Str. dysgalactiae in the 
challenged quarters, as well as confirming the bacterial status  of each cow’s 
mammary gland. As expected the number of viable bacteria in the challenged quarter 
increased from the natural values in the days PI (Fig 5.3) while, at the same time, 
there was no significant effect on the number of viable bacteria in the control 
(uninfected) quarters throughout the study (p < 0.05).  The bacteria shed in the milks 
from the infused quarters had the appearance and growth characteristics of Str. 
dysgalactiae.  The bacterial counts peaked between days 2 and 4 PI, cow 1 peaked on 
day 3 at 8.72 log CFU per ml, cows 2 and 3 peaked on day 2 at 8.797 and 9.28 
respectively, cow 4 reached its peak on day 3 with 8.7 log CFU per ml.  For animal 
welfare reasons, the cows were monitored during the following 30 d PI (results not 
shown) to ensure that all animals were restored to regular udder health and normalised  
in terms of low bacterial levels in milk   
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 time (d)   time (d)   
Figure 5.3 The individual colony forming units (log CFU/ml) of the Str dysgalactae for both the challenged quarter and the control.  The CFU was measured from 
7  
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d preceding to intra-mammary challenge until d 18 PI.  
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5.4.5. Bacterial sequestration assay  
  
From the moment that infection had taken hold, as reflected in the higher milk SCCs, 
the bactericidal sequestration assay was undertaken on the milks from both the 
inoculated and control quarters.  It was found that the milks from the challenged 
quarters of all cows were more effective at restricting E. coli O111 growth PI 
according to the reduced log CFU per ml for cows numbered 1 to 4 by 6.81, 6.69, 6.8, 
and 7.93 respectively.  This effect was most notable between D1 and D7 PI.   The 
corresponding control quarters in all four cows were significantly less effective at 
reducing growth of the assay strain (p < 0.05).  These healthy (control) quarters of all 
animals remained stable in terms of Complement efficacy throughout the trial (Fig 
5.4).  Overall, it can be concluded that the increased effectiveness (p < 0.05) of the 
challenged quarters at restricting growth of the assay bacterium (E. coli O111) reflects 
an increased Complement response at a localised level, i.e., within the individual 
infected quarter, but not that of the mammary gland (udder) as a whole.  
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Figure 5.4   Complement activity in milks was assessed using the bactericidal sequestration assay from both challenged and control quarters.  Measurement 
as  
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reflected by the total viable counts from (log CFU/ml) during performance of the bactericidal sequestration assay 
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5.4.6. C5a ELISA assay    
  
Complement component C5a is an important inflammatory marker that is activated 
late in the cascading pathway during activation of the innate immune response.  An 
Enzyme Linked Immunosorbent Assay (ELISA) was performed to quantify C5a in 
order to establish if elevated levels of this component coincided with greater 
inactivation of the bactericidal sequestration assay target microorganism (E. coli 
O111), and provide further evidence of increased Complement activity.   Related 
studies indicate that C5 may be produced in the epithelial cells of the mammary gland; 
hence, it is an effective marker to allow the complement activity to be monitored at a 
key juncture of the Complement pathway (Stevens et al., 2012).  The C5a ELISA 
assay indicated that there was significantly greater (p < 0.05) levels of C5a in the 
infected quarters compared to the control quarters (Fig 5.5), thus confirming that the 
Complement system is active in the individual infected udder quarters.   
 
  
Figure 5.5 Levels of complement component C5a as determined by an ELISA assay 
completed on the milks from both the control and challenged quarters of the individual cows  
5.5. Discussion    
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Inflammation of the mammary gland is mostly triggered when pathogenic  
microorganisms enter via the teat canal, following which both the innate and specific 
immune systems work in combination to defend the affected area (Tasnim, 2014).  In 
this study, the mammary immune response of four dairy cows was challenged by 
inducing a controlled case of mastitis, using a known strain of Str. dysgalactiae.  
Mastitis is a persistent inflammatory condition which is categorised as either clinical 
or the sub-clinical in dairy cows.   Subclinical mastitis is associated with increased 
SCC, can give rise to a reduced milk yield (ISO, 2006) and impact negatively on milk 
quality criteria. It is reported that mastitis cases cost the US dairy industry 
approximately $2 billion yearly due to the reduced milk production (Sordillo, 2009).  
Milk SCC is commonly linked to milk payment regimes for off-farm milk and ideally 
should not exceed 200,000 cells per ml, as otherwise financial penalties are frequently 
imposed.  On the other hand, milk from a healthy quarter has been described as 
containing reduced bacterial growth and not exceeding 100,000 cells/ml (Pyörälä, 
2003).  The type of pathogen may not be known they can still induce less elevation in 
the SCC.  High SCC affects the quality of the milk by contributing to increased rates 
of lipolysis and casein hydrolysis (Riollet et al., 2002).  The somatic cells also known 
as leucocytes represent the specific immune response to infection as the mammary 
gland tries to contain the invading pathogen. Adaptive immunity involves highly 
specific constituents (e.g. T-cells, B-cells, leucocytes, phagocytes, antibodies and 
immunoglobulins) which detect specific molecular structures on the surface of the 
invading pathogens (Hannson et al., 2002).  The significant increase in Complement 
activity in mammary quarters with high SCC as shown in this study confirms that the 
innate immune system works in parallel with the localised specific immune response 
in the mammary gland (p < 0.05).    
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Some cow to cow variation encountered during the study may be attributed to genetic 
variation which is known to be associated with differences in mastitic response (Rupp 
and Boichard, 2003).  A genetic evaluation system was implemented in France in  
2010, which assessed the occurrence of clinical mastitis in three dairy breeds – 
Montbéliarde, Normande and Holstein (HO) (Govignon-Gion et al., 2015).  Low 
heritability of clinical mastitis has been documented, however, some correlations with 
other traits may hold some potential answers.  The results indicate high correlations 
(often>0.50, in absolute value) between clinical mastitis and somatic cell score (SCS), 
longevity and some udder traits.    
  
In challenge tests, the mastitis-inducing strain, Str. dysgalactiae, inoculated into the 
mammary gland of the four cows studied was based on a strain isolated previously 
from an incidence of mastitis in the MDPC herd.  This Gram-positive strain is credited 
with a significant number of both clinical and subclinical infections (Hogan et al., 
1989, Todhunter et al., 1990).  The strain is considered to have characteristics of both 
a contagious and an environmental pathogen.  Previously, it was isolated from 
mammary glands exhibiting the signs of infection, and may be transferred during 
milking (Marth and Steele, 2001).   
  
As expected, SCC increased from base levels in the inoculated quarter in the hours 
and days following inoculation, thus confirming that the infecting Str. dysgalactiae 
pathogenic strain had triggered tissue inflammation in the affected mammary quarter.  
It has been previously reported that the duration of inflammation may be longer than 
the length of infection, and as Complement plays a major role in inflammation this 
would support the improved Complement response we have seen during the first 4d 
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PI (Pyörälä and Mattila, 1987).  Moreover, bactericidal sequestration assay counts in 
the non-infected (control) quarter were largely unaffected throughout the trial period, 
thus confirming that the innate immune response was mainly localised.    
  
No other pathogenic bacteria were tested from the milk samples, which confirmed 
that the increase in SCC was as a direct response to Str. dysgalactiae inoculation.  
Reference milk culture methods in combination with selective media supported the 
screening process to confirm the presence of Str. dysgalactiae (Hillerton, 1999).    
  
The ELISA test based on its specific determination of Component C5a, a chemotactic 
protein known for its recruitment of inflammatory cells, in the freshly collected milk 
samples provided added confirmation that Complement was the key innate immune 
factor at work in combating the induced-mammary infection.  Thus, the extent of 
association between activated Complement response and raised SCC as an 
inflammatory indicator of individual mammary quarters may be worthy of further 
research. Additional data would need to be generated to establish whether the 
differences between the inactive (healthy quarter) and activated (high SCC quarter) 
Complement levels may be correlated with SCC and / or provide an indirect measure 
of the animal’s capacity to combat mammary infection.   
It has been identified that the incidence of mastitis in cows is directly linked to 
variation in mammary gland physiology and the efficiency of the mammary gland 
defence system (Sordillo and Streicher, 2002).  It is, thus, reassuring to know that 
milk drawn from healthy quarters during periods of mastitic infection in adjoining 
quarters is not exposed to transmission of elevated levels of immune components 
(assuming of course, that milk from the affected quarter is isolated from entering the 
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food chain, usually in conjunction with therapeutic intervention).  Overall, the study 
provides key insights into the innate immune response in the mammary gland when 
triggered by S. dysgalactiae spp. Dysgalactiae inoculation.  Hyperimmunisation of 
lactating dairy cows with specific antigens is frequently employed to induce increased 
antibody activity in the milks collected from these animals. One example is a 
commercial bovine colostral whey preparation containing enriched levels of 
immunoglobulins intended to enhance the immune and bacteriolytic responses of 
calves (Hammarström and Weiner, 2008). Oral administration of milks collected from 
hyper-immunised cows improved the incidence of acute colitis and maintained 
intestinal homeostasis in mice models (Wang et al., 2014).  Unfortunately, there is 
little published information on how Complement activity in milk is affected following 
hyper-immunisation of selected dairy cows. The current induced-mastitis study 
proved that the Complement response was of a local nature i.e., confined to the 
affected milking quarter. However, it is reasonable to expect that a systemically-
triggered response following hyperimmunisation is most likely to be manifested also 
by increased Complement activity in addition to the release of specific antibodies. 
Further research which monitors for changes in Complement as a result of hyper-
immunisation of dairy cows is recommended. In exploring the potential for generating 
therapeutic preparations based on generated antibodies, there is considerable interest 
also in the release of cationic host defense peptides (HDP) which are known to be 
transcriptionally regulated and dependent on stimulus and cell type. Furthermore, 
HDP are regulated and/or coordinated in conjunction with the expression of other 
entities of innate immunity and acute inflammation.  
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Chapter VI Determination of bovine breed variation on Complement activity in 
freshly withdrawn milk  
  
  
  
  
  
  
  
  
  
  
  
6.1.Abstract  
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The overall purpose of this study was to examine the Complement activity, a key 
marker of the innate immune system, present in milk of different breeds.  In previous 
Chapters, the order to magnitude of antimicrobial response to the bacterial 
sequestration assay used to monitor Complement has been shown to be almost 
comparable in biological efficacy for both bovine and human milks  (Maye et al., 
2015).  Specific studies conducted with bovine milk have identified that Complement 
activity is diminished following heat treatment or cream partitioning thus it was 
important to consider potential ways to increase this activity in the milk produced.  It 
has been seen that there is some cow to cow variation which prompted the question 
as to whether cow breed may play a role to in the increased availability of this major 
humoral component (Kelsey et al., 2003; Dillon and Veerkamp, 2001).  In order to 
test this hypothesis, the complement levels between 7 cow breeds, to include pure- 
and crossbreeds, Norwegian Red, Jersey, Holstein, Kerry, Friesian, Norwegian Red 
crossbreed and Holstein Friesian crossbreed was assessed.  A bactericidal 
sequestration assay was utilised for the detection of Complement in milk, whereby, 
the extent of growth inactivation of E. coli O111 was measured and the response was 
used as an indicator of presence and activity of Complement.  The results show that 
the Norwegian Red purebred limited growth of the Complement sensitive strain to  
6.249 log CFU/ml, which was closely followed by the Kerry purebred (6.922 log 
CFU/ml E. coli O111).  Further to this a previously reported transformed E. coli O111 
strain was transformed by correctly integrating the p16Slux plasmid which meant the 
strain could be monitored throughout growth using bioluminescent measurements.  In 
addition, the levels of key complement pathway component, C5a, were quantified 
using an Enzyme Linked Immunosorbent Assay (ELISA).  The results of this assay 
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identified that the Kerry cows had highest levels of active C5a with 0.00786 
mg/1000ml, the Norwegian red purebred cows had levels of 0.00736 mg/1000ml 
closely followed by the crossbreed Norwegian red crossbreed with levels of 0.00647 
mg/1000ml.    
  
6.2 Introduction  
  
Mastitis is one of the most prevalent diseases of cattle. Various studies have reported 
breed-dependent differences in the risk of developing this disease.  Among two major 
breeds, Jersey cows have been identified as having a lower prevalence of mastitis than 
Holstein cows. It is well established that the nature of the initial innate immune 
response to infection influences the ability of the host to clear harmful bacterial 
pathogens.  Whether differences in the innate immune response to intra-mammary 
infections explain, in part, the differential prevalence of mastitis in Holstein and 
Jersey cows remains unknown.  When estimating heritability and selection, it was 
found that cases of clinical mastitis in first lactation Norwegian Cattle were affected 
by selection for other breeding traits (Heringstad et al., 1999).  Due to the 
multifactorial nature of mastitis, management may include a series of activities, i.e., 
dry cow therapy, prevention of transmission of infection as well as the improvement 
of the immune system (Halasa et al., 2007).   
  
Irish dairy farmers with the support of the research arm of the country’s Agriculture 
and Food Development Authority (Teagasc) have combined cattle breeding 
programmes with improved husbandry practices in order to achieve better milk 
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production performance and increased resistance to disease in their dairy herds, 
particularly with respect to udder health and the incidence of somatic cell counts in 
milk (Beecher et al., 2010).  Up to the mid-1980's, the predominant dairy cow breed 
in Ireland was British Friesian and its crossbreeds (Cattle breeds, 2014; Dillon and 
Veerkamp, 2001).  Holstein Friesian was gradually introduced later in individual 
farms due to their high performance dairy production traits.  A certain proportion of 
Jersey cows are frequently included in dairy herds because of their exceptionally high 
milk compositional averages of approx. 6% butterfat and 4% protein, along with milk 
yields of up to 8500 kg.  The introduction of other European cattle breeds led to the 
identification of Norwegian Red for its overall milk production and udder health 
performances (Begley et al., 2009a; Begley et al., 2009b) under Irish dairy husbandry 
practices. Dairy cattle with enhanced and balanced immune responses are known to 
have a lower occurrence of disease including mastitis (Thompson-Crispi et al., 2014).  
Improved immune response to external and internal stimuli including pathogenic 
micro-organisms was strongly associated with improved response to vaccination and 
colostrum quality (Mallard et al., 2011).  A particular focus was on exploiting the 
animal’s own immune response genes.  The genetic selection for mastitis is 
considered to be a potential strategy for improvement of overall udder health.  Nordic 
countries have included mastitis in their genetic evaluation since 1978 with proven 
improvement in udder health (Govignon-Gion et al., 2015).  Other genetic selection 
approaches currently used in the dairy industry include high immune response (HIR) 
technology, genomics to improve disease resistance or immune response, as well as 
the  
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ImmunityC™ sire have been deployed to enhance animal welfare and food quality 
while maintaining favourable production levels in order to feed a growing population 
(Thompson-Crispi et al., 2014).  While these methods have addressed improving milk 
quality, composition and in conjunction with mastitis control programs, there is a 
concern that cattle may become more prone to infection due to the widening range of 
mastitis pathogens being encountered (Bradley, 2002).  Sorg et al (2013) compared 
the innate immune response in vitro of two ancient and two modern dairy cattle breeds 
using RT-qPCR and ELISA techniques in an attempt to establish whether ancient 
cattle breeds not selected for high milk yield had a stronger phenotypical resistance 
to mastitis than modern high yielding breeds.  They found a higher basal expression 
in the ancient breeds studied and that only parts of the toll-like receptor pathway 
(TLR) pathway had higher expression levels than modern breeds.  Rainard and Riollet 
(2006) concluded that many questions need to be answered before the variability of 
the genes governing innate immunity can be harnessed to curb mastitis in dairy 
ruminants.  
  
With previous work focussed mainly on characterising Complement markers 
generated by the innate immune system, it was opportune to compare milk samples 
from a cross section of Irish dairy cows selected according to breeding status 
(purebreds and crossbreds) for the presence of Complement activity and potential 
indication of the innate immune status of each breed.  The milk sampling programme 
was undertaken with the following purebred dairy cows: Norwegian Red, Holstein,  
British Friesian, Jersey and Kerry, as well as crossbred Norwegian Red and Holstein- 
Friesian.    
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6.3 Materials and Methods  
  
6.3.1. Milk collection and analysis  
  
Freshly-drawn milk from individual cows selected from the Teagasc bovine genetics 
database were bulked according to breed following collection at a number of sites: 
Moorepark Dairy Production Centre (MDPC), Teagasc research farms and Teagasc 
associated dairy farmers in the south of Ireland during mid-lactation - May to July 
2014, during which the animals were primarily grass-fed.  The SCC of the freshly 
collected milk was determined using a Bentley Somacount 300® (Bentley Instruments 
Inc., Chaska MN, USA), and an SCC of  ≤100,000 cells per ml was the considered 
the threshold value for healthy milk samples (ISO 2006; ISO, 2008).  All samples 
were analysed for TBC using an ISO reference method (ISO, 2004; ISO, 2013).    
  
6.3.2. Animal selection  
  
Based on statistical power calculations, a minimum of 17 dairy cows from each of 7 
breeds were required for milk sampling using the bovine genetics databases 
developed by Teagasc and the Irish Cattle Breeding Federation (ICBF).  To ensure 
we would have the minimum amount at the end of the study 18 cows were included 
from each breed.  The selection criteria for the breed of interest were set at >90% and 
~50% for purebred and crossbred cows, respectively.  A review of the recent health 
history of selected lactating cows took into consideration time of calving and any 
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intervention with antibiotic therapy. This was followed by monitoring of SCC for 3 
weeks before initialisation of milk sampling.  On 3 consecutive days, at morning 
milking time (approx. 08.00 h), milk samples were aseptically collected from 4 pure- 
and 2 crossbreeds: Norwegian Reds, Holsteins, Jerseys, Friesians, Kerry, Norwegian 
Red crossbreed and Holstein-Friesian crossbreed.   
  
6.3.3. Control preparation  
  
Freshly collected bulk raw milk was heat-treated at 56 °C for 30 min to ensure 
complete inactivation of the complement protein (Korhonen et al., 2000).  All samples 
were screened using ISO methods (ISO 2013, ISO 2004), and also the milks were 
streaked on Nutrient and Luria Bertani agar.    
  
6.3.4. Bacterial strains, media, and chemicals  
  
Escherichia coli O111 (E. coli NCTC 8007, serotype O111 K58 (B4)) a pathogenic  
Complement sensitive strain, was purchased from Health Protection Agency Culture 
Collections (Health Protection Agency Culture Collections, Porton Down, Salisbury 
Wiltshire, SP4 0JG UK). The strain was routinely grown in Luria-Bertani (LB) 
medium 37 °C with shaking.  When required, the antibiotic erythromycin (Sigma 
Chemical Company, St. Louis, MO) was added at a concentration of 500 mg/ml to 
the broth to select for the growth of transformed E. coli O111.  
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6.3.5. Bactericidal sequestration assay  
  
Escherichia coli NCTC 8007, serotype O111 K58(B4) was the serum susceptible 
strain selected – also known to be frequently isolated from neonates affected by 
gastroenteritis (Reiter and Brock, 1975a).  This strain was stored as a stock culture 
and grown on LB agar and sub-cultured in LB broth.  It was grown overnight at 37 
°C and adjusted to 3x108 CFU per ml for the assay.  To the round bottomed 96-well 
plate sourced from Sartsedt (SARSTEDT Ltd., Sinnottstown Lane, Drinagh – 
Wexford Ireland). 20µl of the E. coli O111 culture was added to each well.  To this 
80µl of milk sample to be tested was added under aseptic conditions.  The plate was 
then put into a shaking incubator (Model Mini 4450 SHKA4450-1CE, Fischer 
Scientific, Ballycoolin, Dublin) at 37°C and 100 rpm for 2h.  After this time the plate 
was transferred to a laminar flow hood and 20 µl sample was taken from each well.  
These samples were tested for viable counts using LB agar (Merck KGaA, Darmstadt,  
Germany) and the pour plate method.  
  
For the transformed strain, it was conducted in the same way; however, the strain was 
initially grown in overnight in LB broth with Erythromycin.  When the growth 
reached 3x108 CFU per ml, the culture was centrifuged and a pellet formed.  The 
pellet was washed twice and then finally solubilised in LB broth.  The remaining steps 
of the assay proceeded as described for the WT E. coli O111.               
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6.3.6. Real time monitoring of the E. coli O111 p16Slux in Milk  
  
E. coli O111 NCTC 8007 described above was transformed with plasmid p16Slux as 
described in Maye et al., (2016) at the Biosciences Research Institute, University 
College Cork Ireland.  Once the p16Slux plasmid was successfully inserted as 
previously described (Riedel et al., 2007) the strain was incubated with the individual 
milk samples which had been aseptically collected from the 6 breeds of cows.  These 
were run alongside a complement-inactivated control to confirm that the reduction in 
E. coli O111 p16Slux numbers were attributable solely to the activity of Complement 
present.    
  
6.3.7. C5a ELISA assay    
  
C5a ELISA kit (BlueGene, Shanghai, China) assay was used to detect the convergent  
C5a Complement protein in the milks.  This kit was specifically prepared to detect for 
Bovine Complement C5a.  Phosphate buffer saline (PBS) solution was used as a  
negative control.      
  
6.3.8. IgM ELISA assay  
  
An IgM ELISA kit designed specifically for bovine IgM (Bethyl laboratories, USA) 
was used to detect the presence of IgM in the different breed milks.  Phosphate buffer 
saline (PBS) solution was used as a negative control.      
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6.3.9. Statistical Analysis  
  
Statistical analysis was undertaken on data generated from analyses of triplicate milk 
samples from 18 cows per breed resulting from collection at 3 separate intervals over 
the time period referred to in Section 2.1.1.at other consecutive 3-day intervals. Data 
was analysed using an SPSS program (SPSS Inc., Released 2009. PASW Statistics 
for  
Windows, Version 18.0. Chicago: SPSS Inc.).     
  
6.4 Results   
  
6.4.1 Comparison of Complement-associated bactericidal activity in different 
breeds of cows   
  
The bactericidal sequestration assay used to determine Complement activity relies on 
the unique sensitivity of the E. coli O111 strain to the presence of Complement. 
Consequently, a reduction in colony forming units (CFU) is observed.  Hence in the 
context of this study, a lower survival of E. coli O111 would indicate a breed with 
higher levels of active Complement.  There was a significant difference (p < 0.05) in 
growth of the E. coli sequestration strain in the milks of the 7 cow breeds when 
compared to the heat-treated control (Fig 6.1), notably the milk produced by the 
purebred Norwegian Red (followed by the Kerry purebred) cows was effective at 
restricting the growth of the bacterial sequestration strain.  The results  (Table 6.1) 
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indicate that the control (heat-treated milk, 56°C for 30 min) with a value of 9.113 is 
significantly higher than the milks of the seven breeds, whereby, the Norwegian Red  
(purebred) restricted E. coli O111 to an average growth of 6.249 log CFU/ml, next 
the  
Kerry (purebred) had 6.922 log CFU/ml, which was closely followed by the 
Norwegian red (crossbreed) with a measurement of 7.072 log CFU/ml, the final four 
breeds; Holstein (purebred), Friesian (purebred), Jersey (purebred), Holstein Friesian 
(crossbreed) exhibited growth levels of 7.600, 7.364,  8.257, 7.162 log CFU/ml 
respectively - the lower value indicating a more effective Complement response.  
Enhanced cell reduction factors of 2.864 and 2.191 (p < 0.05) were measured 
following incubation of the E. coli O111 culture with the freshly collected milks from 
Norwegian Red and Kerry cows, respectively, both of which were significantly 
different (p < 0.05) from the control.   It was also observed that the Norwegian Red 
cross-bred appears to conserve a significant amount of the bactericidal capability (p 
< 0.05) of its parent pure-breed.  A one-way analysis of variance test confirmed that 
all samples were more effective at limiting the growth of the E. coli O111 when 
individually compared to the negative control.  Due to this significant result for all 7 
milks, it was necessary to conduct post hoc tests which allow further exploration of 
the differences among the means.  The post-hoc statistical analysis comparing the 
individual data sets provided further confirmation that the Kerry and Norwegian red 
were significantly more effective at impeding viable E. coli O111 when compared to 
the other 5 breeds.  
   
Cow  Control  Norwegian Red  Norwegian Red X  Holstein  Friesian  Jersey  Holstein Friesian  Kerry  
1  9.000  6.200  7.009  7.652  7.484  7.812  7.145  6.944  
2  9.125  6.204  7.071  7.845  7.252  7.822  7.098  7.008  
3  9.321  6.279  7.141  7.781  7.236  7.922  7.252  6.948  
4  8.988  6.259  6.749  7.660  7.419  8.038  7.202  6.803  
5  9.259  6.208  6.900  7.629  7.432  8.136  7.106  7.073  
6  9.621  6.537  6.949  7.460  7.313  8.146  7.337  6.988  
7  8.255  6.129  6.953  7.966  7.213  8.215  7.166  7.089  
8  8.951  6.350  6.940  7.760  7.466  8.237  7.137  7.126  
9  9.235  6.399  7.021  7.173  7.581  8.309  7.132  7.029  
10  9.148  6.350  7.177  7.714  7.373  8.364  7.298  7.062  
11  8.956  6.266  7.106  7.721  7.391  8.367  6.980  7.002  
12  9.258  6.204  7.370  6.905  7.234  8.375  7.194  7.168  
13  8.785  6.278  7.274  7.491  7.331  8.379  7.234  7.069  
14  8.899  6.184  7.128  7.705  7.484  8.385  6.979  6.874  
15  9.259  6.207  7.225  7.553  7.252  8.408  7.040  6.740  
16  9.855  6.330  7.076  7.516  7.236  8.491  7.257  7.075  
17  8.890  6.059  7.065  7.681  7.419  8.581  7.203  5.726  
18  9.230  6.043  7.151  7.599  7.432  8.646  7.162  6.868  
Average  9.113  6.249  7.072  7.600  7.364  8.257  7.162  6.922  
Standard Dev  0.339  0.119  0.147  0.244  0.109  0.240  0.099  0.319  
  
Table 6.1 Results of the Bactericidal sequestration assay performed on the milks from each of the 18 cows from 7 breeds – Milk was hygienically collected on three 
consecutive morning milking and the assay was completed immediately after collection.   
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Figure 6.1 Total viable counts of E. coli O111 (log10 CFU/ml) following 2h  incubation in 
the bacterial sequestration assay with samples, Control (heated bulk bovine milk 56°C, 30  
min), after 2 h incubation at 37°C and 200 rpm.   
  
6.4.2 Measurement of Complement pathway component C5a   
  
An additional ELISA assay was carried out with the objective of quantifying levels 
of active C5a of the Complement cascade.  Component C5a is known to be an 
inflammatory mediator which is intimately involved in neutrophil recruitment, hence 
it was selected in this study as a biological marker to confirm Complement system 
activity (Riollet et al., 2000).  This assay was carried out on freshly collected milk 
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samples on the day of collection.  The ELISA analyses of all 7 breeds (Fig 6.2) 
confirm that the C5a component was dependent on breed of cow.    
 
  
Figure 6.2 Average C5a ELISA assay results for the 18 individual milk samples from each 
of the breeds as well as one control (bulk milk heat treated at 56°C for 30 min).    
  
Moreover, a one-way analysis of variance test of the data show that individually each 
breed was significantly different from the control (p < 0.05), which implied all breeds 
had some C5a component present.  Post-hoc statistical analysis confirmed that 
analogous to the bactericidal sequestration assay the Kerry and Norwegian red 
purebreds had significantly more C5a present when compared to the other pure- and 
crossbreds (p < 0.01).  Yet again the Norwegian red crossbreed maintained a 
significant level of C5a and was not significantly different from its purebred 
equivalent, consequently, it may be considered that there is a level of stability of these 
qualities of the Norwegian Red breed (p < 0.05).  This analysis appears to confirm 
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that the increased E. coli O111 inhibition can be accredited to increased activity of 
this key Complement component among these two breeds.        
The relationship between the C5a ELISA assay and the bactericidal sequestration 
assay was investigated using the Pearson product-moment correlation coefficient.  
This test recognised a strong negative correlation between the two variables, i.e., 
higher Complement C5a levels corresponded with greater inhibition of E. coli O111, 
thus confirming that the milks of the Norwegian red and Kerry breeds stood out in 
terms of higher Complement activity.     
  
6.4.3 Measurement of Immunoglobulin M using ELISA assay  
  
Immunoglobulins are strongly associated with the antimicrobial capabilities of bovine 
milk; in order to confirm that the antimicrobial effect seen in the 7 breed milks was 
due to increased levels of Complement instead of Immunoglobulins it was decided to 
assess the levels of IgM in the milk samples.  An IgM ELISA completed on the milk 
samples collected from the 7 breeds and control samples (Fig 6.3) confirmed that IgM 
levels for all 7 breeds were comparable.    
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Figure 6.3 IgM ELISA assay results for the milks collected from the 7 pure- and cross- 
breeds as well as from the Control sample which is produced by heat treating bulk tank milk  
at 56°C for 30 min.    
  
6.4.4 Somatic cell counts of milk samples   
  
SCCs remained low (< 200,000 cells) throughout the trial, and there was no 
significant difference (p < 0.05) between each breed (Fig 6.4).  Given that such low 
SCC levels reflect positively on the udder health status of the animals, the observed 
responses can therefore attributed to Complement present in the milk and not due to 
other immune components (Schukken et al., 2003).  There was no significant 
difference among individual cows within breeds.    
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 Red Red X Friesian 
  
Figure 6.4 The average somatic cell counts (log) for all 7 breeds was monitored throughout 
the trial, all remained at normal levels and there was no sign of sub- clinical or clinical  
infection in any animal included in the study.  
  
6.4.5 Use of transformed E. coli O111 for real time monitoring in breed variation raw 
bovine milks   
  
Previous work by the authors successfully transformed E. coli O111 with the p16 Slux 
plasmid.  This adaptation allows specification of the sequestration technique by lux 
tagging of the target microorganism in order to elaborate more substantively changes 
taking place in Complement activity due to breed variation.  This test adaptation by 
the authors provides supplementary information in relation to the direct performance 
of the breed-specific variation, e.g., incorporation of the p16 Slux plasmid ensures 
that the Complement response may be measured throughout incubation and for a 
longer time (24h), and thus provide detailed monitoring of the viability of E. coli 
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O111, the assay marker microorganism.  The lux-tagged E. coli O111 strain was 
inserted into a modified bactericidal sequestration assay whereby the amount of 
bacteria was reduced (i.e., 3 X 105 CFU per ml) to slow the growth of E. coli O111 
and avoid the death phase due to lack of nutrients available.  As seen in Fig 6.5 the 
control (heat treated raw milk, 56°C 30 min) allows the bacteria to grow and thus, 
increase bioluminescence over time.  
    
Figure 6.5 The bioluminescent image captured of the 96 well plate monitoring growth of E. 
coli (ROI) during bactericidal sequestration assay of after inoculation with transformed E.  
coli O111 and incubated over 24h  
.  
Without exception, all 7 breeds reduced the bioluminescence over time; however, the 
Norwegian Red pure-breed and the Kerry pure-breed animals were capable of 
reducing the growth of E. coli O111, and thus, the bioluminescence emitted most 
efficiently (p < 0.05). After 24h, there was little or no bioluminescence remaining in 
the wells containing milks produced by these breeds.      
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When lux tagged E. coli O111 was employed, region of interest (ROI) values were 
monitored in order to quantify the effect of Complement; ROI was estimated by 
selecting an area of particular interest in individual wells of 96-well plates. As 
expected, the control (raw bovine milk, heated 56°C, 30 min) allowed the bacteria to 
grow and attain a stationary growth phase from approx. 7h until 24h (Fig 6.6).    
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Figure 6.6 Region of interest readings from Xenogen IVIS of E. coli O111 (log) during 
incubation at 37°C for 24h in the Control and the 7 different breed milks following   
inoculation with transformed E. coli O111   
However, all milks from the seven breeds slowed growth at an earlier 5h stage, 
leading to eventual decline of the culture numbers from 7h onwards.  The milk of the 
Kerry breed was more efficient at reducing growth to 3.96 (log) according to the ROI 
measurement.  Overall, the bioluminescence signal for all breeds was reduced, this 
result correlated well with the other testing methods described above; the ROI 
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readings had reduced to 4.28, 4.83, 4.94, 4.56, 4.53 and 5.00 following incubation 
with Norwegian Red purebred, Norwegian Red crossbred, Holstein purebred, 
Holstein crossbred, Friesian purebred and Jersey purebred, respectively.        
6.5 Discussion   
  
Overall, the milks of Norwegian red and Kerry purebred dairy cows exhibited better 
Complement response when challenged by the bactericidal sequestration assay, thus 
confirming that these breeds possess more robust innate immune systems – assuming 
that the migration of Complement across the mammary tissues into milk reflects its 
concentration in the blood sera.  In addition, it was observed throughout the study that 
the Norwegian red crossbreed maintained strong Complement activity, which would 
suggest that the genes relevant for this protein system are stable and well maintained 
within the Norwegian Red breed.  The superior immunity of the Norwegian Reds was 
evident during a study which compared Norwegian crossbreeds to purebred Holstein 
calves - the Holsteins had reduced antibody-mediated immunity compared with 
Norwegian Red-Holstein crossbred calves (Cartwright et al., 2011).  Norwegian red 
cows have improved immunological and genetic resistance to disease.  This has been 
associated with specific MHC genes which were found to be essential in eliciting a 
suitable immune response against invading pathogens (Kulberg et al., 2007).  As we 
know, there has been increased emphasis placed on clinical mastitis studies and the 
effect on milk production (Seegers et al., 2003).  Breeding programs based on this 
selection criteria have affected the total merit index of the Norwegian red breed 
(Heringstad et al., 2003), therefore, it may be that the elite-sires that have been 
selected in recent years, on average, are genetically less susceptible to infection. 
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Furthermore, this genetic improvement of mastitis resistance via selection is feasible, 
which may also imply that improved Complement activity could be selected for using 
similar breeding programmes.    
The  Complement activity measurements reported in this study may help to provide 
an underlying explanation for why superior overall cow health has been observed in  
the Norwegian Red pure and crossbreeds (Begley et al., 2009b).  The strong 
Complement activity performance of the Kerry breed alongside the Norwegian Reds 
correlates with the awareness of a high level of genetic conservation within the former 
breed.  Geographically, the breed enjoys considerable isolation in the south-west of 
Ireland, where it appears to have maintained a stable set of genes to maintain the 
integrity of the breed (MacHugh et al., 1998).  Norwegian Red, on the other hand, is 
a dairy breed that was established in 1935 by the crossing of dairy breeds with several 
Scandinavian breeds, including the Norwegian Red and -White, Red Trondheim and 
the Red Polled Østland (Bai 2011).  Complement activity data according to the 
bactericidal sequestration assay is further corroborated by an ELISA measurement of 
component C5a where the Norwegian red purebred and the Kerry purebred again 
performed the best, with levels of 0.00737 and 0.00787 mg/1000ml respectively.  The 
IgM ELISA assay also confirmed there was no significant difference in IgM levels 
between the 7 breed milk samples; furthermore, there was no significant difference 
between the 7 milk samples and the control.  The control value was similar to the 
other milks which is consistent with those reported by Mainer et al., (1997).  The 
effects of different heat treatments on IgG, IgA and IgM studied by these authors 
showed that denaturation increased with higher temperature and longer holding times. 
Furthermore, IgM would not be denatured when exposed to the Complement 
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inactivation temperature (56oC for 10 min).  Bannermann et al. (2008) found that the 
temporal response of a wide range of physiological markers following infection was 
similar between Holstein and Jersey cows, and concluded that the innate immune 
response at udder health level between these two dairy breed is highly conserved 
despite previously reported differences in mastitis prevalence, as well as genotypic 
and phenotypic traits.  However, innate immune capabilities have been observed using 
comparative genomics to identify heritability of the candidate genes associated with 
the specific innate immune response (Jann, 2009). The selected genes are being 
sequenced in different cattle populations to discover novel single nucleotide 
polymorphisms (SNP) in order to differentiate genetic differences between individual 
animals.  
This study indicates that the selection of bovine phenotypes for breeding, based on 
studies of immunology and other functional characteristics could assist in improving 
the heritability of mastitis resistance and improved overall health.  This supposition 
has already been found to have a positive effect on mastitis resistance in the NR dairy 
cow population (Heringstad, et al., 2003).  Furthermore, epidemiological modelling, 
quantitative trait loci detection and expansion of additional functional genomic testing 
could provide valuable tools in understanding the genetic determination of mastitis 
resistance.  Along with this, this study could also provide improved characteristics for 
fertility and protein yield.    
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Chapter VII General Discussion  
  
  
  
  
  
  
  
  
  
  
From the outset, the experimental work described in this thesis aimed to confirm the 
existence of Complement in bovine milk and to establish some comparability with the 
biological efficacy of that occurring in human milk. Scientific interest over the years 
has been preoccupied primarily with the role of Complement in human milk 
(Ogundele, 1998, Ogundele, 1999), but there is little documented research about its 
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presence in normal bovine milk since Reiter and Brock (1975a) monitored 
Complement-mediated bactericidal activity of antibodies to a serum-susceptible strain 
of E. coli of the serotype O111 in colostrum and post-colostral milks.  The milks 
screened as part of this initial study established that Complement is active in raw 
bovine milk and that the magnitude of its bacterial sequestration activity appears to 
approximate closely that of human milk.   This finding is encouraging, because it puts 
a spotlight on the fate of Complement during the course of processing bovine milk, 
hence leading to the subsequent study which investigated the effects of a range of 
thermal treatments. It was clear from this that Complement was relatively easily 
inactivated in milk under moderate heating conditions (56oC, 30 min) i.e., at less  than 
batch pasteurisation temperatures, as reflected by the diminished capacity (p < 0.05) 
of milk to inactivate the serum-sensitive strain (Korhonen et al., 2000).  Protein-based 
milk antimicrobial agents generally tend to be easily inactivated by heat treatment 
(Oram and Reiter, 1968). Thus, it is not surprising to encounter relatively low levels 
of Complement activity in retail pasteurised milk, a product normally subjected to 
regulatory high-temperature, short-time (HTST) heating requirement of 72oC with 
holding time of 15s.    
Equally revealing was that the residual Complement activity levels were lower in 
reduced-fat variants of retailed pasteurised milks, which pointed towards a possible 
association between milk fat and Complement.  However, the reduced activity due to 
the fat removal indicates a fat-associated component.  Of the antimicrobials with 
known associations to the fat fraction and MFGM such as lactoferrin, lactoperoxidase, 
immunoglobulins, lysozyme, not all components are as significantly affected at 56°C 
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for 30 min (Ford et al., 1977, Bullen and Rogers 1972, Ludikhuyze et al., 2001 and 
Dominguez 1997)   .   
A gravity-induced creaming study established that, as fat content increased in the 
upper cream layer, bactericidal capacity increased as monitored by the sequestration 
assay.  This appeared to be analogous to the agglutination phenomenon that occurs 
during creaming in cow’s milk whereby its cryoglobulin content forms clusters of 
milk fat globules, bacteria and somatic cells that migrate upwards. The distinguishing 
feature in the case of Complement is that the study was undertaken at 15oC instead of 
the lower temperature (4oC) where cryo-agglutination normally occurs.  However, it 
confirms that Complement has some form of physical association with globular fat, 
particularly its MFGM, which was also evident from an additional study which 
revealed a greater bacteriostatic effect of buttermilk compared to skim milk during 
laboratory simulation of the butter-making process - buttermilk is known to be 
enriched with MFGM components released during cream churning (Corredig et al.,  
2003).     Geer & Barbano (2014) reported that the interaction between somatic cell’s 
and immunoglobulins play an important role in inducing aggregation of fat, somatic 
cell’s, bacteria, and spores to rise throughout gravity separation. These authors 
postulate that the SCC improves buoyancy of the aggregates, facilitating their rise to 
the top.    
  
A transformation of E. coli O111 with the p16 Slux plasmid enabled the strain to emit 
bioluminescent light, so that the bacterial sequestration assay could be measured 
quickly and also facilitates a high throughput method for assessing Complement  
activity in milk.      
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The immune status of the lactating animal and the corresponding Complement level 
detectable in milk puts the spotlight on such as factors as animal health status and 
breed.      
The inflammatory response induced in the individual mammary immune reactions of 
four cows using a known strain of Str. dysgalactiae indicated that Complement 
activity increased only in the milks of the affected quarters, thus confirming that the 
innate immune system was acting at the site of local infection and not systemically in 
the form of increased Complement permeation into milk even from healthy quarters.    
  
The study of cow breeds identified that Norwegian Red and Kerry cows exhibited 
greater Complement activity.  Interestingly, there is considerable contrast in the 
lineage of both breeds. The Norwegian Red originated in 1935 following the 
crossbreeding of dairy breeds with Scandinavian breeds in order to improve health 
and fertility, while the Kerry is an ancient Irish breed that is now exceptionally rare. 
In the latter case, innate immunity appears to be well conserved, while in the case of 
the Norwegian Red, targeted crossbreeding succeeded in the creation of a healthy 
dairy cow with a more robust immune system.  This is one step removed from 
targeting the genes and pathways responsible for Complement activation in 
conjunction with a breeding programme to increase Complement activity in milk.  An 
investigation of the manner in which the Complement migrates into milk can improve 
our knowledge about its mode of action and provide an opportunity for the 
preservation of biological effect and development of a new functional product with 
immune-enhancing benefits.     
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As described previously, other antimicrobial constituents are also present in bovine 
and human milk, and while the specificity of the bacterial sequestration assay 
confirms the effects on Complement, it is also worthwhile to consider any parallel 
effects of these other constituents.  Lactoferrin also has a role in the maintenance of 
the inflammatory response and is capable of inhibiting the classical Complement 
pathway (Samuelsen et al., 2004).  In addition to its antimicrobial activity in vivo 
through ironsequestration, specific peptides derived from the N-terminal region from 
both human and bovine lactoferrin, lactoferricin H and lactoferricin B, respectively, 
inhibit the classical complement pathway in the course of controlling inflammation 
triggered by bacterial infection (Samuelsen, et al., 2004). Interestingly, the E. coli 
O111 strain that is susceptible to Complement in bovine serum is equally inhibited in 
iron-saturated sera (Reiter et al., 1975b).  Another serum-resistant strain, E. coli O101, 
was equally uninhibited by unheated and heat-treated serums.  During a preliminary 
study carried out by the authors (results not reported here) it was also observed that 
the serum resistant E. coli O125 was not inhibited to the same levels as the 
Complement sensitive E. coli O111.  
  
Another antimicrobial constituent in milk, which has been reported to be bactericidal 
for specific pathogenic strains in the presence of IgA and Complement component 
C3.  Curiously, there is known to be an increase in lysozyme activity on heating to 
60°C which may be due to its release from the larger components in the milk (Evans 
et al.,  
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1978), however, the loss of Complement activity following heat treatment at 56°C for  
30 min clearly confirms that this anti E. coli O111 activity is not due to lysozyme.    
  
Xanthine oxidase is another milk constituent that increases in activity when fresh milk 
is subjected to different processing treatments, i.e., cooling, heating, homogenization, 
and enzymatic activity.  While initially bound in some form to the fat phase, increased 
enzyme activity is always accompanied by a rise in activity in the skim milk phase.  
A hypothesis for this activity may be that the increased activity is associated to the 
redistribution of the enzyme.  There appears to be a low association with the fat 
fraction  and holding milk for 4h at 60°C does not affect the enzyme activity at all  
(Gudnason et al., 1962).    
  
Bovine colostrum and milk have been recognised as a rich source of immunoglobulins 
which may provide protection when transferred to young infants – so-called ‘immune 
milks’ (Hurley and Theil, 2011).  The effect of heating is immunoglobulin specific, e.g., 
in the case of IgG it is possible to heat treat colostrum at 60°C for one to two hours 
without loss of efficacy (Hurley and Theil, 2011). Existing knowledge on 
hyperimmunised milks is of particular importance for specific microbial diseases 
which cannot currently be treated using chemotherapy, e.g., rotaviruses, antibiotic-
resistant enteropathogens and cryptosporidium.  Milk with increased Complement 
activity and immunoglobulins may act as intervention agents in the prevention or 
treatment of enteric infection (Early et al. 2001). Considerations for the use of these 
milks include issues due to regulation, ethical reasoning which are mainly due to the 
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use of immunepotentiating adjuvants and frequency of immunisation doses. The 
immune- 
supplementation of clinical diets and special infant formulas with specific antibodies 
appears, therefore, to be a challenging future approach. (Hurley and Theil, 2011). 
Other studies should aim to further investigate the factors that influence Complement 
activity in bovine milk and methods to retain its activity during processing.  Treatment 
with milder heat processes could be a potential way to improve activity of the heat 
labile constituents; however, it is essential that these processes fulfil the food safety 
assurance equivalent to pasteurisation.  A new technology which has been recently 
applied to other foods is the use of microwave technologies and, although critical 
control points would need to be maintained, this equipment would appear to have the 
potential to substitute ultra-high heat treatments which are currently used to process 
ready-to-feed liquid infant milk products.  Current patented microwave volumetric 
heating technologies have the capacity to apply microwaves in a flow process, thus, 
enabling the sterilisation of milk products at temperatures up to 12oC lower than 
conventional temperatures (Zadyraka et al., 2015).  Moreover, this could also reduce 
the holding times for the milk product.   Such a process may be applicable for milk 
products and formulations that aim to preserve the original Complement activity of 
its starting materials.          
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